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Abstract 
P53 is a key tumor suppressor and transcription factor protecting us from cancer. The 
wild type p53 protein functions as a regulatory protein, triggering a variety of cellular 
responses to different signals. Activation of p53 can lead to cell division arrest, DNA 
repair, or apoptosis. More than 60% of all human cancers contain p53 mutations. P53 is 
also reported in many studies to play a role in the control of other cellular important 
activities such as angiogenesis and glycolysis. In this study we aimed to to identify novel 
target genes of p53 by investigating the difference in down-stream gene expression of wt 
p53 in a the Saos-2 cell line which is devoid of p53 expression, in comparison to mutated 
form of p53 that has been reported to be associated with cancer and in relation to the lack 
of p53 expression. The aim was also to study protein-protein interactions between p53 
and its protein partners in the different p53 variants. Two different p53 mutations (R249S 
and R273H), considered as hot mutations, were constructed by site-directed mutagenesis. 
The GeneSwitch system was used to make stable inducible p53 cell lines. This expression 
is controlled by mifepristone (inducer). Total proteins were isolated from the different 
cell lines and separated on 2D gels. The total protein expression in Saos-2 cells 
containing wild type p53, R249S or R273H mutants, in addition to cells with no p53 copy 
were compared. The expression patterns of the different samples were similar but not 
identical.  
Our results showed a different expression patterns in some vital proteins. Our results 
suggest a role of p53 in transcriptionally activating the β subunit of Prolyl 4-Hydroxylase 
which plays an important role in angiogenesis. Also our results show different patterns in 
expressing vimentin, which is the most abundant intermediate filament protein in various 
cell types, between the different cell lines. Also our results show a clear difference in the 
protein expression patterns of four proteins, which are essential in glycolysis (TIM, 
enolase 1, α-enolase and aldolase A.) suggesting a role of p53 in the metabolism of 
tumors particularly in glycolysis. Recent studies have implicated some of these proteins 
in cancer if not to p53 as well. Studies dealing with P53 and its partner proteins from the 
total protein using anti V5 antibody were attempted, but was not pursued further due to 
the short time. The way of doing this was proteomics. 
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2DE Two Dimensional Gel Electrophoresis 
2D-gel Two Dimensional Gel separation 
AA (aa) Amino Acid 
AD Adenocarcinoma 
Ant Antibiotics 
APS Ammonium PerSulfate 
ATCC American Type Culture Collection 
ATP Adenosine Triphosphate 
BLAST  Basic Local Alignment Search Tool 
BSA Bovine Serum Albumin 
CA Carbonic Anhydrase 
CDK Cyclin Dependent Kinase 
CHAPS [3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate] 
DMEM Dulbecco/Vogt Modified Eagle's Minimal Essential Medium 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
dNTP Deoxy Nucleotide Triphosphate 
DTT Dithiothreitol 
E. coli Escherichia coli 
EV Empty Vector 
FBS Fetal Bovine Serum 
g Gravity, relative centrifugation force 
HCC Hepatocellular Carcinoma 
HCV Hepatitis C Virus 
IARC International Agency for Research on Cancer 
IP Immunoprecipitation 
IPG Immobilized pH Gradient 
Kb Kilo Base 
kDa Kilo Dalton 
LB Luria-Bertani 
MALDI Matrix Assisted Laser Desorption Ionization mass spectrometry 
MALDI TOF MALDI time-of-flight mass spectrometry 
MS Mass Spectrometry 
MW Molecular Weight 
NAD Nicotinamide adenine dinucleotide 
NCBI National Center for Biotechnology Information 
NSCLC Non-Small Cell Lung Carcinoma 
OD  Optical Density 
P4-H Prolyl 4-Hydroxylase 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PDI protein disulphide isomerise 
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pI Isoelectric Point 
R249S Hot spot mutation in the .p53 gene at aa position 249. Arg is changed to Ser. 
R273H Hot spot mutation in the p53 gene at aa position 273. Arg is change to His. 
RCC Renal Cell Carcinoma 
rpm Round Per Minute 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
Saos-2 Human Osteosarcoma derived cell line, p53-null 
SCC Squamous Cell Carcinoma 
SCO2 Cytochrome c Oxidase 2 
SDM Site Directed Mutagenesis 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
siRNA Small (short) Interfering RNA 




WB Western Blot 
WT (wt) Wild Type 
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Introduction 
P53 or TP53 is a key tumor suppressor transcription factor in the cell. The level of p53 
protein is reported to be very low in normal cells; however, its level increases 
significantly in cells under stress (1). The wild type p53 protein functions as a regulatory 
protein, triggering a variety of cellular responses to different signals Activation of p53 
can lead to growth arrest, DNA repair, or apoptosis (2). P53 protein regulates cell 
responses to DNA damage to keep genomic stability by transactivation and trans-
repression of its downstream target genes (3). More than 60% of all human cancers 
contain p53 mutations (4). Mutations in p53 are frequently found in human cancers 
owing to the loss of tumor suppressor activities (loss of function) as well as to the gain of 
tumorogenic activities (gain of function) (5). Both the p53-regulated genes and interacted 
proteins form a large network of cell system to regulate cell division, DNA repair and 
apoptosis. P53 function is often inactivated or suppressed in human cancers. Thus, 
functional restoration of this pathway is an attractive therapeutic strategy (6). 
 
P53 structure:  
DNA sequence: 
The p53 gene is located on chromosome 17 (17p13), Figure 1. P53 gene is about 20 kb 
composed of 11 exons (2), Figure 2. There is a very large intron between exon 1 and 
exon 2. Exon 1 is untranslated region in the human p53 (7). 
 
Figure 1: Chromosome 17. P53 gene is located on the short arm of the chromosome 
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Figure 2: The p53 gene consists of eleven exons. The pink region denotes the UTR (the 
untranslated region), the blue region denotes the coding region and the grey region denotes the 
internal exons within the introns. Figure is adapted after kind permission from p53 
knowledgebase: http://p53.bii.a-star.edu.sg/index.php (8) 
 
P53 protein sequence (7): 
The tumor suppressor protein p53 is a 393 amino acid transcriptional enhancer 
phosphoprotein that reversibly associates to form tetramers. The human p53 protein 
comprises of several domains, Figure 3:  
1. The amino-terminus part (aa 1-44) contains the transactivation domain, which is 
responsible for activating downstream target genes. 
2. A proline-rich domain (aa 58-101) mediates p53 response to DNA damage 
through apoptosis. 
3. The DNA-binding domain (aa 102-292) is a core domain, which consists of a 
variety of structural motifs. 90% of p53 mutations found in human cancers are 
located in this domain, preferable as a single aa mutation. 
4. The oligomerization domain (aa 325-356) consists of a β-strand, which interacts 
with another p53 monomer to form a dimer, followed by an α-helix which 
mediates the dimerization of two p53 dimers to form a tetramer. 
5. Three putative nuclear localization signals (NLS) have been identified in the C-
terminus, through sequence similarity and mutagenesis. The most N-terminal 
NLS (NLSI), which consists of 3 consecutive Lysine residues to a basic core, is 
the most active and conserved domain. 
6. Two putative nuclear export signals (NES) have been identified. The leucine-rich 
C-terminal NES, found within the oligomerization domain, is highly conserved 
and it has been suggested that oligomerization can result in masking of the NES, 
resulting in p53 nuclear retention. 
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Figure 3: Domains of human p53 protein. Figure is adapted after kind permission from p53 
knowledgebase: http://p53.bii.a-star.edu.sg/index.php (8).  
 
P53 Functions: 
The role of p53 in cell-cycle control: 
The cell cycle is an ordered set of events, culminating in cell growth and division into 
two daughter cells. This process is composed of two basic phases:  Mitosis and the 
Interphase, Figure 4. The Interphase consists of three phases which are G1, S and G2. 
During the cell cycle, chromosomal DNAs are replicated during S phase and equally 
delivered into two daughter cells during the M phase. 
 
Figure 4: The Cell cycle. It is composed: Mitotic phase (M) and interphase. Interphase consists 
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Normally the cell cycle is under tight control through three major checkpoints, especially 
at the transition state from G1 phase to S phase and from G2 phase to M phase. P53 
protein is stabilized in response to these checkpoints in the cell cycle which are activated 
by DNA damage, irradiation, hypoxia, viral infection, or oncogene activation resulting in 
diverse biological effects, such as cell cycle arrest, apoptosis, senescence, differentiation, 
and antiangiogenesis (9). The p53 protein is stabilized and activated by phosphorylation, 
dephosphorylation, acetylation, sumoylation and ribosylation at specific sites, yielding a 
potent sequence-specific DNA-binding transcription factor (9). 
Activation of p53 as a transcription factor causes transactivation of downstream genes, 
leading to cell cycle arrest in G1, before DNA replication, and in G2, before mitosis. 
Also, genes involved in apoptosis are activated by p53 protein (2), Figure 5. 
 
 
Figure 5: P53 role in the cell cycle. P53 is activated in response to activation of cell cycle 
checkpoints as a result of DNA damage or other oncogenic factors. Activation of p53 
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G1 checkpoint: 
Under normal growth conditions, progression through G1 is promoted by D-type and E-
type cyclins and their associated cyclin-dependent kinases (cdk2, cdk4, and cdk6) (10). 
Arrest in the G1 phase of the cell cycle is critical for genomic integrity because it blocks 
entry into S phase and prevents replication of damaged DNA. 
Upon DNA damage, p53 is activated and induces p21WAF1/CIP1, a cyclin-dependent kinase 
inhibitor [reviewed in (11)]. P21 sustains G1 arrest by inhibiting cdk2 and cdk4 activities. 
This inhibition prevents the phosphorylation of pRb, hence the release of E2F from the 
pRb-E2F complex. This blocks transcription of genes required for entry into S-phase by 
E2F, and as a result prevents entry into S-phase since the active released E2F is the 
transcription factor that transactivates the target genes important for the progression of 
cell cycle including cyclin E. (12;13). 
G2/M checkpoint: 
The G2/M checkpoint plays a role in genomic maintenance by preventing segregation of 
damaged chromosomes (10). In order to sustain a G2/M arrest, Cdc2-cyclinB activity 
must be inhibited. p53 regulates many target genes that play critical roles during G2/M 
arrest [reviewed in (10)]. For example, p53 regulates p21 which blocks G2/M progression 
by binding the Cdc2-cyclinB complex and preventing the activating phosphorylation of 
Cdc2 at Thr161 by CAK (14). p53 also induces 14-3-3  which blocks entry into mitosis 
[reviewed in (15)]. Moreover, other p53 targets, such as GADD45, BTG2, REPRIMO, 
B99 (GTSE-1), hematopoietic zinc finger protein (HZF), and MCG10 have been 
implicated in the maintenance of the G2/M checkpoint [reviewed in (10)]. 
S checkpoint: 
The intra-S phase checkpoint is activated when DNA damage occurs during S phase (10). 
Although it has yet to be confirmed, a newly identified p53 isoform called p53 may 
participate in the intra-S checkpoint. This p53 may promote the intra-S arrest by 
inducing p21 and 14-3-3  (10;16).  
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The role of p53 in DNA repair: 
Various cellular insults including chemotherapeutic drugs, chemical carcinogens, 
gamma-irradiation, ultraviolet-irradiation (UV), reactive oxygen species (ROS), and 
endogenous stressors lead to DNA damage. Failure to repair damaged DNA results in cell 
death or oncogenic transformation, neither of which is a desired outcome for a biological 
system. Depending upon the type of DNA lesion, eukaryotic cells utilize multiple DNA 
repair pathways to mend damaged DNA including nucleotide excision repair (NER), 
mismatch repair (MMR), base excision repair (BER), translesion synthesis (TLS), 
homologous recombination (HR), and non-homologous end joining (NHEJ) pathways. 
Not surprisingly, studies show that p53 promotes genomic integrity by regulating the 
DNA repair pathways. In addition, many p53 target genes participate in the DNA repair 
process. Furthermore, p53 directly modulates DNA repair through transcriptional-
independent mechanisms (10).  
 
The role of p53 in Apoptosis: 
Under situations of extreme DNA damage, p53-dependent transcription is well known to 
stimulate apoptosis (10). P53 regulates the transcription of genes in the apoptotic 
cascade. Two of such genes, Bax and Bcl-2, are important in the mitochondrial pathway 
of apoptosis (13). The Bax (pro-apoptotic gene) and Bcl-2 (anti-apoptotic gene) form 
homo- and heterodimers to control the mitochondrial permeability for the release of 
cytochrome c and AIF (apoptosis inducing factor). P53 can transactivate Bax gene while 
transrepressing Bcl-2 gene, thus leads cell to apoptosis (13). 
P53 promotes the extrinsic pathway through upregulation of the TRAIL receptors, death 
receptor-4 (DR4) and death receptor-5 (DR5, KILLER) [reviewed in (17)], as well as the 
FAS receptor (CD95) and the FAS/APO-1 ligand (18). P53 activates the intrinsic 
apoptotic pathway through multiple mechanisms [reviewed in (19)].  
 
The role of p53 in Senescence: 
Senescence is well known as p53-dependent process and is characterized by an 
irreversible growth arrest of cells that remain metabolically active (20). Senescence can 
be triggered by DNA damage or oncogene activation. Cells entering senescence are 
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characterized in addition to permanent cell cycle arrest, by an altered transcriptional 
program, a large flattened morphology, and a failure to replicate their DNA. p53 
regulates both replicative senescence and premature senescence (10). 
 
The role of p53 in Differentiation: 
Differentiation may be another way in which p53 eliminates damaged cells. Stem cells 
possess the ability to self-renew and are often resistant to cell cycle arrest and apoptosis, 
making them prime targets for tumorogenesis. Thus, p53 may promote differentiation of 
stem cells into a less malignant cell type competent to undergo cell cycle arrest and 
apoptosis (10). 
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Figure 6: DNA damage and activation of p53. In normal cells, DNA damage activates p53 which 
in turn binds to DNA and transcriptionally regulates target genes responsible for G1 arrest (p21 
which is CDK inhibitor) and DNA repair (GADD45). If the repair succeeded, cells continue the 
cycle as normal cells. If not, p53 activates apoptosis gene (BAX) and drives the cell to 
programmed cell death. This network is compromised in the absence or mutated p53 resulting in 
tumors. This Elsevier image is adapted from http://www.humpath.com.  
P53 mutations: 
Because of the important role of p53 in regulating normal cell growth, p53 is frequently 
mutated in cancers. It has been reported that more than 60% of cancer cells contain 
mutated p53 genes (4). Mutations can be either upstream of p53 preventing DNA 
damage/oncogene overexpression signals from activating p53, or downstream of p53 
preventing p53 target genes from executing their functions in cell cycle regulation 
[reviewed in (5) ].  
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The International Agency for Research on Cancer (IARC) in Lyon, France has 
constructed an online TP53 mutation database. The current version of the database is 
R11, released in October 2006. The R11 release contained 23,544 somatic mutations, 376 
germline mutations and functional data on more than 2300 mutant proteins http://www-
p53.iarc.fr/Statistics.html. The statistics of IARC shows a dramatic increase of the p53 
mutations detected in relation to cancer, Figure 7. 
 
Figure 7:  Growth of the dataset of somatic p53 mutations. (IARC TP53 database, R11 release, 
October 2006) (21). 
 
73.7% of p53 mutation in the IARC database are missense mutations caused by singular 
amino acid substitutions, although deletion and insertion can occur (5), which lead to 
either expression of a mutant protein (90% of cases) or absence of a protein (10% of 
cases) (21). Mutations of p53 are distributed predominantly in the DNA binding domain, 
especially in the codons 175, 245, 248, 249, 273, and 282, which are often referred to as 
“hot spots” mutations, Figure 8.  
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Figure 8: Codon distribution of somatic p53 mutations. p53 hot spots mutations have higher 
occurrence percentage as single base substitution. (IARC TP53 database, R11 release, October 
2006) (21). 
 
Mutations in p53 were found in tumors in a wide variety of organs. Figure 9 shows tumor 
site distribution of mutations according to IARC. 
 
Figure 9: Tumor site distribution of mutations according to IARC, tumor site distribution of 
mutations according to IARC (21). 
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Mutations constructed in this study: 
The two mutations constructed in this project were R249S and R273H, which are located 
within the “hot spot” region. Both mutations are positioned in the DNA binding domain. 
In the first mutation R249S, the wild type sequence AGG, which codes for the amino 
acid arginine (R), has been mutated into the sequence AGC that codes for the amino acid 
serine (S). In the second mutation R273H, the wild type sequence CGT, which codes for 
arginine (R) as well, was replaced by the mutant sequence CAT, which codes for histidin 
(H). R249S is associated mainly with hepatocellular carcinoma and to a lesser extent with 
Non Small Cell Lung Carcinoma (NSCLC) according to IARC. R273H is associated 
mainly with colo-rectal cancers and to less extent in breast cancer according to IARC. 
Table 1 summarizes the characteristics of the two mutations. 
 
Table 1: The two mutations constructed in this study 
Mutant WT sequence Mutant sequence Prevalent Cancer Sites 
R249S AGG AGC Liver, Lung 
R273H CGT CAT Colo-rectal, Breast, Ovary, Brain 
 
Figure 10 shows modulated images of p53 protein indicating the positions 249 (A: WT 
and B: mutant) and 273 (C: WT and D: mutant). 
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Figure 10: 3D modulated images of p53 protein indicating the position 249 (A: WT, B: R249S) 
and the position 273 (C: WT, D: R273H) Figures were generated using analysis tools in p53 
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P53 as a target for cancer therapy: 
P53 has long been considered a prime target for cancer therapeutic modulation (22). 
Since many p53 mutants with loss of transcriptional activity might still retain its ability to 
activate apoptosis through the transcription-independent pathway, there is considerable 
excitement that this newly identified mechanism will ultimately lead to a new generation 
of cancer therapeutics (23). Many chemotherapeutic agents cause DNA damage and 
activate the p53 pathway to induce growth arrest and apoptosis (24). Functional 
restoration of this pathway is an attractive therapeutic strategy (23). P53 is maintained at 
low levels in cells, largely through MDM2-mediated degradation. Thus, rescue of p53 
function by disrupting MDM2-p53 interaction is considered to be an efficient approach 
for anti-cancer therapy (25). 
It was recently published in Biotech News International (October 2006) that researchers 
have shown that an approach to cancer treatment based on disrupting the activity of the 
p53 inhibitor Mdm2 is effective in preventing the development of tumors without causing 
premature aging (26). 
In recent years, a number of therapeutic approaches aiming at modulation of the p53 
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Aim of study 
The tumor suppressor activity of p53 results from its ability to transcriptionally activate 
and repress a wide variety of target genes that in turn regulate among other things: cell 
cycle arrest, DNA repair, apoptosis, and suppression of angiogenesis (27). The p53 tumor 
suppressor activity is also a result of p53 involvement in cellular functions by protein-
protein interactions (28). Functional diversity depends on the association with a large 
subset of partner proteins, which dictates the type of activity and corresponding 
selectivity (28).  
P53 gene expression has been examined at the mRNA level, though many possibilities 
exist for intervention at the protein level, as the p53 protein is known to interact with 
many other cellular proteins in order to mediate its many important roles. In this study we 
analyzed changes in protein expression in Saos-2 cells in the absence of p53 and in 
presence of mutated p53 and compared them to the protein expression in Saos-2 cells 
containing wild type p53.  
Our aims of this study were: 
- To investigate the role of p53 in downstream gene expression in relation to the lack of 
p53 expression or the expression of mutated form of p53 that was reported to be 
associated with cancer.  
- To study protein-protein interactions between p53 and other proteins in the different 
p53 variants. 
- By studying different mutants we try to identify the difference in the downstream 
gene expression between these mutants. 
- By studying the protein expression of different mutants we try to see if there is any 
biomarker that can be linked to any mutant or only associated with wt which might 
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Table 2: Plasmids 






Cloning vector for p53 gene 
cloning and expression in 
mammalian cells. The expressed 






Invitrogen  Control of gene expression of the 




Table 3: Materials used for site-directed mutagenesis 
Material Source Purpose 
DpnI restriction enzyme  
 
Stratagene, La Jolla, 
CA, USA 
Digestion of the methylated 
parental strand 
Pfu Ultra DNA polymerase Stratagene  
Template Pdest/HA-wtp53 Stratagene  
DNTP Mix Stratagene  
 










R249S AGG AGC F: TGAACCGGAGCCCCATCCTC 
R:GAGGATGGGGCTCCGGTTCA 
20 




Table 5: Primers used for sequencing 
Reagent Source Sequence No. of 
Bases 
pGene Forward Primer Invitrogen 5´-CTGCTATTCTGCTCAACCT-3´ 19 
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Table 6: Biological materials 
Material Source Purpose Description 
E. coli XL1- blue cells 
Genotype: recA1, endA1, 
gyrA96, thi-1, hsdR17(rK-
,mK+), supE44, relA1, λ-, lac-





Competent cells to be 
transformed with the 
plasmid including the 
gene of target so the 
DNA amount will be 
multiplied.  
Dam+ bacterial 
cells so can 
methylate the 
transformed DNA 
and protect it from 
being destroyed by 
the cell. 
Saos2 cells LGC 
Promochem –
ATCC, USA. 
To establish inducible 
mammalian cell lines 
with the p53 gene 
Human 
Osteosarcoma p53- 
null cell line 
Anti-V5-Horse Horse Radish 
Peroxidase (HRP) antibody 
Invitrogen Immunoprecipitation  
 
Table 7: Materials used for cell culture 
Material Contents Source Purpose 
FBS Fetal Bovine Serum Invitrogen  






Dry powder Instamed® DMEM, 
2,6 mM NaHCO3, 20 mM Hepes 
Acid and Hepes Na. pH: 7,2. 
Osm: 280 
Prepared locally in 
the Institute of 
Medical Biology 
IMB, University of 
Tromsø Uitø 
 
Media for cell 




DMEM + Ant + 
10% FBS 
DME + 60 mg/L Penicillin-G 
(Sigma-Aldrich) + 100 mg/L 
Streptomycin (Sigma-Aldrich)  






DMEM + 20µg/L Zeocine + 








a brand of EMD 
biosciences, La 
Jolla, CA, USA 
Cell culture after 
transfection 
DME+FBS 1:9  IMB, Uitø Freezing cells 
PBS 137 mM NaCl, 2,7 mM KCl, 4,3 
mM Na2HPO4, 1,47 mM 
KH2PO4. pH: 7,2-7,3. Osm:320 






150 mM NaCl, 50 mM tris pH 8, 
1% Triton X-100. Sterile filtered 
Prepared locally in 
our lab 
Lysis buffer for 
protein isolation 
LB media 10 g/L Trypton, 5g/L Yeast 
Extract, 10 g/L NaCl, 1,1g/L 
Glucose, pH: 7,4 
IMB, Uitø Growing E. coli 
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 Table 8: Materials used for western blotting 
Reagent Contents Source 
SDS PAGE sample application 
buffer 
100 mM Tris-HCl pH 6,5, 4% SDS, 
0,05% Bromophenol blue, 20% 
Glycerol, 200 mM DTT (added fresh), 
Milli Q-Water  
Prepared locally 
in our lab. 
Blue Plus 2 Prestained Standard  Invitrogen 
Biotinylated SDS-PAGE 
standard kit, broad range AP. 
 Bio-Rad, Cat. No. 
161-0322 
NuPAGE 4-12% Bis Tris gel, 
1,5 mm X 10 well 
 Invitrogen 
NuPAGE Transfer buffer   Invitrogen 
MES SDS-PAGE running buffer  Invitrogen 
Transfer (blotting) buffer 25 mM Tris base pH: 8,3, 192 mM 
glycine, 20% v/v methanol (added 
fresh) 
Prepared locally 
in our lab. 
PBS-tween (PBST) PBS buffer + 0,1% Tween 20 Prepared locally 
in our lab. 
Blocking buffer PBS-Tween + 5% (w/v) nonfat, dry 
milk 
Prepared locally 
in our lab. 
Western wash buffer 10 mM Tris-HCl pH 9,5, 10 mM NaCl, 
1 mM MgCl2 
 
Prepared locally 
in our lab. 
Anti p53 antibody  Zymed, CA, USA
Goat anti mouse IgG (H+L)  Invitrogen 
CDP star assay buffer pH 9.5  Applied 
Biosystems, USA 
Immobilon ™-P membrane  Millipore 
cooperation, USA
 
Table 9: Kits 
Kit Source Purpose 
QuickChange®Multi Site Directed 
Mutagenesis kit 
Stratagene  Site-directed mutagenesis 
QIAGEN® plasmid purification kit Qiagen, Hilden, 
Germany 
Plasmid extracting and purification 
GeneJammer® Transfection kit Stratagene Transfection 
RC DC Protein Concentration Assay Bio-Rad Measuring protein concentrations 
 
Table 10: Materials used for immunoprecipitation 
Material Source Purpose 
Anti-V5-HRP Antibody Invitrogen Binding to V5 epitope 
Protein-G Sepharose™ 4 Fast Flow Amersham Pharmacia 
Biotech, Ltd, Sweden 
Forming Antibody-Protein 
complexes on the sepharose 
beads 
Protease Inhibitor cocktail Sigma-Aldrich, P8340  Inhibiting proteases 
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8 M urea, 4% (w/v) CHAPS, 10% (v/v) glycerol, and 0.002% (w/v) 
bromphenol blue, (add at time of use) 0.2% (w/v) DTT (Amersham 
biosciences, Uppsala, Sweden) and 0.5% (v/v) Pharmalyte (pH 3-
10) (Amersham) 
SDS equilibration buffer I 6 M urea, 30% glycerol, 2% (w/v) SDS and 50 mM Tris-HCl, pH 
8,8, (added at time of use) 1% DTT. 
 
SDS equilibration buffer 
II 
6 M urea, 30% glycerol, 2% (w/v) SDS and 50 mM Tris-HCL, pH 
8,8, (add at time of use) 2.5% (w/v) iodoacetamide (GE Healthcare, 
UK) and a small amount of bromphenol blue 
8% Acrylamide gel (160 x 160 x 1.5 mm) 22.9 ml dH2O, 8.6 ml Acrylamide/Bis (40%) 
(Bio-Rad, Hercules, CA), 11 ml Resolving buffer (1,5 M Tris-HCl, 
pH 8,8), 425 µl 10% (w/v) SDS, 210 µl 10% APS: Ammonium 
Persulfate (Kastman Kodak company, Rochester, NY) and 21 µl 
TEMED (Amersham) 
The running buffer 25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS, pH 8.3 
Agarose  0.8% agarose (Invitrogen) in running buffer and a small amount of 
bromphenol blue 
Polyacrylamide gel cast Acrylamide/Bis (40%), Resolving buffer (1,5 M Tris-HCl, pH 8,8), 
SDS 10% 
Staining SimplyBlue™ SafeStain (Invitrogen) 
SYPRO Ruby (Bio-Rad, CA, USA) 
Strips 7 and 13 cm IPG Immobiline® DryStrip, pH: 3-10 (GE Healthcare, 
Uppsala, Sweden). 
PDQuest 8.0 2-D analysis software (Bio-Rad) 
IPG® buffer Amersham /GE Healthcare) 
IPGphor™ (Pharmacia 
Biotech) 
Equipment used for 1st dimension 
 
PowerPac HC™   (Bio-
Rad)   
Equipment used for 2nd dimension 
 
 
Table 12: Other materials used in this study 






MW Standard used for agarose gels 







Bio-Rad Protein concentration assay 
Acetone MERCK, Darmstadt, 
Germany 
Organic solvent that can be used for concentrating 
diluted protein samples 
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Methods 
The Gene switch™ system (Invitrogen®) (29) 
The development of gene-technology has made it possible to produce large amounts of 
proteins by cloning the gene of interest in an expression vector. Expression vectors are 
often plasmids or viruses. The expression vector can be introduced in a suitable organism 
where the protein of interest can be expressed. The wild type and different variants (EV, 
R249S and R273H) of the protein can be expressed. 
One of the major functions of p53 is to induce cell apoptosis, it becomes unlikely to 
create a stably transfected cell line with a constitutive expression of p53 (3). Therefore 
we have created four stable cell lines with inducible p53 expression for wt, empty vector 
R273H and R249S. 
The pGene/V5-His-wtp53 vector is capable of replicating in both bacteria and 
mammalian cells. Such a vector capable to replicate in two unrelated species is called a 
shuttle vector. 
The GeneSwitch™ System for inducible mammalian expression is ideal for experiments 
that require the absolute lowest non-induced expression levels. The system is composed 
of two major components. The first component is the pGene/V5-His inducible expression 
vector, Figure 11A. Expression of our gene of interest (p53) is under the control of the 
hybrid promoter consisting of Saccharomyces cerevisiae GAL4 upstream activating 
sequences (UAS) (Giniger et al., 1985; Wang et al., 1994) linked to the TATA box 
sequence from the adenovirus major late E1b gene (Lillie and Green, 1989). Without 
additional factors, the GAL4-E1b promoter is transcriptionally silent. 
The second component of the GeneSwitch system is the pSwitch regulatory vector, 
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Figure 11: Plasmid vector maps of A) pGene/V5-His (B), prior to gene insertion, and b) pSwitch. 
The wild type p53 gene was cloned into the pGene/V5-His vector. The mutations in p53 were 
introduced by site-directed mutagenesis. pSwitch vector is used to allow control the gene 
expression of the cloned p53 variant in pGene, Figures are adapted from Invitrogen (29).  
 
The regulatory fusion protein functional domains are explained below:  
• Gal4 DNA Binding Domain (Gal4-DBD) to bind the regulatory protein to the 
GAL4-E1b promoter 
• Truncated human Progesterone Receptor Ligand Binding Domain (hPR-LBD) 
that undergoes a conformational change when it binds the progesterone 
antagonist, mifepristone 
• Transcription activation domain from the NF-B transcription factor p65 
(p65AD) to activate transcription from the silent GAL4-E1b promoter (our gene 
of interest). 
Low basal transcription of the regulatory fusion protein occurs in the cell. The synthetic 
steroid, mifepristone (Invitrogen), is used as an inducing agent to activate transcription of 
the gene of interest as well as transcription of the regulatory fusion protein.  
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This works as follows, in the absence of mifepristone, the conformation of the hPR-LBD 
region prevents the regulatory fusion protein from activating transcription from the 
GAL4-E1b promoter. When mifepristone is added and binds the hPR-LBD region, the 
regulatory fusion protein assumes a conformation that permits it to stimulate transcription 
from the GAL4-E1b promoter, Figures 12 and 13.  
Accordingly this leads to activation of the gene of interest located on the vector 
pGene/V5-His. In addition, four Gal4 binding sites upstream of the minimal HSV TK 
promoter on pSwitch can bind the regulatory fusion protein. Therefore, adding 
mifepristone also up-regulates production of the regulatory protein, Figure 13. The 
increased levels of the GeneSwitch™ regulatory protein result in induction of the gene of 
interest from pGene/V5-His to levels that can approach those of viral promoters.  
The following figures are adapted from Invitrogen manual for GeneSwitch System. 
 
 
Figure 12: Regulating the expression of the gene of interest, the p53 gene in this case (29). 
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Figure 13 Regulating the expression of the gene of interest, the p53 gene in this case (29). 
 
 
Figure 14: Illustrates the steps of expressing the gene of interest in GeneSwitch System (29). 
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Expression of p53 in pGene/V5-His-wtp53 vector: 
The p53 is expressed as a p53-V5-His-tag fusion protein in the pGene/V5_his-wtp53 
vector. A fusion protein is a protein created through genetic engineering of two or more 
proteins/peptides. This is achieved by creating a fusion gene, which includes replacing 
the stop codon of p53 gene and substituting it, in frame by tryptophan (W) then 
appending the DNA sequence of the V5 epitope in frame to the p53 coding sequence. The 
normal p53 stop codon (UGA) is changed to (UGG) which codes for Tryptophan (W) by 
site-directed mutagenesis such that the following peptides are fused in-frame. This 
reconstructed p53 coding sequence can be expressed by the cell as a single fused protein. 
The size of this reconstructed p53 gene insert is approximately 1.3kb giving rise to 
protein of 48 kDa. 
 
Site-Directed Mutagenesis (SDM): 
Site-directed mutagenesis, also known as site-specific mutagenesis is the method used to 
create specific mutations in vitro, in a given DNA sequence. Methods for site-directed 
mutagenesis can be classified into two groups: non-PCR (polymerase chain reaction) 
based and PCR based. Today, PCR based methods are most commonly used. Site 
directed mutagenesis could alter DNA sequences at a single site or at multiple sites. 
Alternatively, base pairs may be substituted, inserted or deleted (30).  
 
PCR based mutagenesis: 
The site-directed mutagenesis in this study was done by running a PCR (polymerase 
chain reaction) mutagenesis. The principles of a PCR mutagenesis are identical to the 
“basic” PCR principles; except that the primers used to introduce mutation(s) (mutagenic 
primers) are complementary in sequence and are in opposite direction (30). 
Making mutations: 
The specific method employed involves creating primers (forward and reverse) that are 
identical to the parental DNA with the exception for one specific base. The primers 
anneal to the parental single-stranded DNA template, and a high fidelity DNA 
polymerase (pfu) synthesizes the remainder of the plasmid. Site-specific mutations are 
most commonly designed in a synthetic oligonucleotide referred to as the mutagenic 
M. Belal Al-Jabri, 2006  Materials and Methods 
 
 24  
oligonucleotide (or primer). For best results, mutations should be placed in the middle of 
the oligonucleotide sequence (30). An overview over PCR mutagenesis is outlined in 
Figure 15.  
 
Figure 15: An overview of the PCR site-directed mutagenesis. Figure is adapted from Stratagene 
manual of site directed mutagenesis kit  
 
The Quick Change® kit (Stratagene) was used in all generated mutations in p53. This 
method is a PCR based mutagenesis method employing two complementary primers in 
opposite directions, but containing the desired mutated sequence (30). Purified DNA of 
the entire cloned wt p53 gene in pGene/V5-His6 was used as the DNA template. The 
primers used to generate the two mutations R249S and R273H are presented in Table 4. 
DpnI treatment: 
After the PCR mutagenesis, the PCR mixture will contain a mix of newly synthesized 
plasmids with the desired mutation and parental DNA strands that do not contain the 
mutation (wt). To remove the undesired parental DNA containing the wt gene, the 
mixture was treated with DpnI. DpnI is an endonuclease that digests only methylated and 
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hemi-methylated DNA at the target sequence 5`-GMeATC-3`. Since the PCR is done in 
absence of methylated bases and methylating enzymes, the only DNA that would be 
digested is the methylated, non-mutated-parental DNA. This is because the parental DNA 
has been isolated from Escherichia coli, and almost all E. coli strains are dam+ 
methylated and therefore susceptible to DpnI digestion. (QuickChange® Multi Site 
Directed Mutagenesis Kit). 
 
Experimental steps of SDM: 
QuikChange (Stratagene) protocol was followed in the site-directed mutagenesis. The 
PCR mixture for site-directed mutagenesis of the different mutations was composed of 
1X reaction buffer, 50ng DNA template pGene/V5-His6 50pmol of each forward and 
reverse primer, Table 4, 10mM of each dNTP, and distilled water to a total volume of 
50µL. 2.5U of Pfu Ultra DNA polymerase (Stratagene) was added subsequently. The 
PCR cycle was as follows: 1 cycle at 95°C for 3 minutes, 16 cycles at 95°C for 30 
seconds, 70oC for 13 minutes and hold at 4°C. 
Following the PCR, 10µL of the product was mixed with 5µL loading buffer and loaded 
into a well in 0.8% agarose electrophoresis gel.  BenchTop 1kb DNA ladder (Promega, 
Madison, WI, USA) was used as a molecular weight standard.  The gel was run at 120V 
for 1 hour. 
10U of DpnI (Stratagene) was added to each PCR mixture and mixed gently and were 
then incubated at 37°C for 1 hour. 
 
Competent cells and transformation: 
 Competent cells are bacteria that can accept extra-chromosomal DNA or plasmids. 
Transformation is defined as the uptake of DNA. This means that the pGene/V5-His-p53 
vector is “transferred” into E. coli cells. The aims of transformation are to: 
- Seal the staggered nicks in the vector, introduced by the site directed mutagenesis.  
- Amplify the vector of interest.  
A bacterium does not normally take up much free DNA from the environment; competent 
bacteria cells are therefore used in transformation. Competent cells are cells treated with 
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(among other things) a high salt concentration solution. The pores in the cells will open, 
and DNA may enter more easily in these cells. Also, when performing the transformation 
the cells are heat shocked, and this increases the transformation efficiency.  
 
Transformation: 
The pGene/V5-His-p53 containing wt or the engineered mutants were transformed into 
competent E. coli cells using the XL1 blue strain (Stratagene). The plasmid DNA was 
purified using QIAGEN Plasmid Purification kit: mini and midi protocols, (QIAGEN, 
Hilden, Germany). 
 pGene/V5-His empty vector DNA was used as control and referred to as Empty Vector 
EV. Wild type p53 and mutants were cloned into pGene plasmid and sequenced before 
the start of this study (El-Gewely unpublished data). The engineered p53 mutant R273H 
was also cloned in this vector. (El-Gewely and Stromberg unpublished data). 
Experimental steps of transformation: 
Growing E.coli for plasmid preparation: 
25 ml of LB media containing 10mM MgSO4 and 100 µg/ml ampicillin was added into 
each of five sterile flasks. Using a sterile hot needle, colonies were picked from the plates 
marked with different plasmids and inoculated accordingly in the five flasks:  
- pGene/V5 His-Empty Vector 
- pGene/V5 His-R249S 
- pGene/V5 His-R273H 
- pGene/V5 His-wtp53 
- pSwitch 
The flasks then were incubated in a shaker at 37° C overnight. The cultures were 
transferred to tubes and centrifuged at 6000 x g for 15 minutes (6000 rpm in Sorvall GSA 
rotor). The tubes containing the cell pellets were placed on ice and a 4 ml resuspension 
buffer (provided with the kit as P1) was added to each tube. Then 4 ml lysis buffer (P2) 
were very gently mixed and incubated for 5 minutes at room temperature. The same was 
repeated with neutralizing buffer (P3). 
After 15 minutes of incubation on ice, tubes were centrifuged at ≥ 20.000 x g for 30 
minutes (13000 rpm in a Sovarall SS-34 rotor). The supernatants were then applied on 
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equilibrated QIAGEN-Tip 100 and allowed to enter the resin by gravity flow. After 
washing with the washing buffer (4ml), all the QIAGEN-Tip 100 were moved to new 
tubes and DNA was eluted by adding 5ml QF buffer provided with the kit. In order to 
precipitate the DNA, isopropanol (0.7 Volume) was added to the eluted DNA, mixed and 
centrifuged immediately at ≥15000 x g for 30 minutes. The supernatant was carefully 
decanted and the DNA was washed with 70% ethanol, dried then re-suspended in TE 
buffer then frozen at –20°C until used. 
 
DNA Sequencing:  
DNA sequencing was made according to the Sanger et al., 1977 method using chain-
terminating nucleotide analogs (31) 
Experimental steps of DNA sequencing: 
Two sequencing reactions were run to sequence both strands of DNA using forward and 
reverse primers.  
pGene forward primer, Table 5. 
BGH reverse primer, Table 5. 
The reaction mixture was as follows: 
300 ng ds DNA template,  
2.5X BigDye 3.1,  
3.2 pmol pGene forward or reverse primer,  
5X sequencing reaction buffer  
Sterile distilled water to a total volume of 10µL. 
The reaction cycling was as follows:  
1 cycle at 96°C for 5 minutes,  
30 cycles at 96°C for 10 seconds,  
30 cycles at 50°C for 5 seconds,  
30 cycles at 60°C for 4 minutes,  
hold at 4°C.  
Tubes were centrifuged in a microcentrifuge. The capillary system part of DNA 
sequencing was done locally in the Department of Medical Genetics, Tromsø University, 
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using 3130X Genetic Analyzer, Applied Biosystems/HITACHI). Sequence analysis was 
done using “BLAST 2 SEQUENCES” in NCBI BLAST engine for local alignment. 
http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi  
 
Mammalian Cell Culture:  
Saos-2 cells used in this study: 
A human osteosarcoma Saos-2 cell line (ATCC, USA) was used as the transfection 
recipient of the p53 variants. Saos-2 cell line is p53-null cell line 
Establishing permanent cell lines with inducible p53 variants: 
The cell cultures were cultivated in incubators 37°C with the presence of O2, 5 % CO2 
and humidity. 
Transfection: 
Transfection is the delivery of foreign molecules such as DNA into eukaryotic cells. Two 
principally transfection approaches can be used, transient or stable transfection. Transient 
transfection is when the DNA is introduced to the nucleus of the cell, but does not 
integrate into the chromosomes. Expression of transiently transfected gene can typically 
be analyzed within 24-96 hours after introduction of the DNA. But a stable transfection, 
as was performed in this study, is when the transfected DNA is either integrated into the 
chromosomal DNA or maintained as an episome. Using the selective drugs resulted in 
selection of the cells containing the desired vectors and eliminating the cells that does not 
contain the desire plasmid constructions. 
Transfection was performed using GeneJammer® Transfection kit (Stratagene®, CA, 
USA).  
Experimental steps of transfection: 
The same amounts of plasmid DNA (2µg DNA) were transfected into equal numbers of 
cells from the same batch. 2.5 x 105 exponentially growing cells were inoculated in each 
well of 6 wells culture plate and grown in appropriate volume of DMEM + Serum + 
Antibiotics for 24 hours prior to transfection. The DNA amounts were detected according 
to Stratagene GeneJammer® Transfection kit as outlined in Table 13. 
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Table 13: DNA amounts used for transfection 




















Mass at 4:1 
ratio 
0.4 µ g 1.6 µg 1.6 µg 1.6 µg 1.6 µg 
Corresponding 
Volume 
2.2. µL 4.6 µL 10.6 µL 5 µL 5.3 µL 
Tubes 1 & 2 2.2. µL 0 0 0 5.3 µL 
Tubes 3 & 4 2.2. µL 4.6 µL 0 0 0 
Tubes 5 & 6 2.2. µL 0 10.6 µL 5 µL* 0 
 
Transfected human osteosarcoma Saos-2 cells, grown in DMEM with 10% fetal bovine 
serum (FBS) (Invitrogen), were then selected using both 20 µg/L** Hygromycine 
(Invitrogen), selection agent for the pSwitch regulatory plasmid, and 20 µg/L** Zeocin 
(Invitrogen), selection agent for the pGene/V5-His-p53. The cells were then transfered to 
flasks where stable colonies formed in two weeks in average. When the flasks were 
approximately 70% confluent, 1 x 10-8 M of the mifepristone was added to induce p53 













*The transfection of the mutation R273H was done in a separate experiment under the same conditions. 
** The concentrations of zeocine and hygromicine have been optimized in an earlier experiment based on 
minimal toxic concentration. (Dana Kate Mersich and Raafat El-Gewely, unpublished data). 
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Isolating Total Proteins from the stably engineered cell lines after 
induction of gene expression:  
When isolating total proteins, the proteins can be in either denatured or non-denatured 
state. To be able to “fish out” the p53 protein and its partners by immunoprecipitation, it 
is essential that the proteins keep their native conformational structure. Therefore, non-
denaturating, non-reducing method was used in order to keep the proteins in their native 
status. This method uses lysis buffer containing Triton X-100 to which protease inhibitor 
cocktail was added. 
Experimental steps of protein isolating: 
The monolayer cultures were washed with PBS at room temperature and the flasks were 
incubated on ice for 1 hour after adding the Triton X-100 lysis buffer. Then the cells were 
scraped off using rubber policeman. The cell membrane and cell organelles were 
removed after centrifuging the whole contents for 10 minutes at 16000 x g at 4°C. 
The protein concentrations were measured using protein concentration assay (RC DC 
BioRad) by making standard curves based on known concentrations of Bovine Serum 
Albumin (BSA). Absorbance was read using spectrophotometer (Medinor produkter, 
MediSpec III) at 750 nm and the unknown concentrations were calculated from the 
equation of the standard curve. 
Western Blot: 
It was important that the stable cell lines made express p53 in an inducible manner. So in 
order to verify that the cell lines express p53 when induced with mifepristone, and only 
when induced with it, a western blotting was performed.  
Experimental steps of western blot: 
Electrophoresis: 
Total proteins were extracted from Saos-2 cells with different p53 variants, both induced 
and non-induced p53. 15 µg extract and 10 µl SDS-PAGE sample application buffer 
containing freshly added 200 mM DTT was mixed. Biotinylated standard was diluted in 
sample buffer 1:20. The samples were heated (85-95°C) for 10 minutes using a heat 
block and were then cooled and centrifuged at max speed for a few seconds. The samples 
were applied on the gel and the gel was run for 50 minutes at 200 V. 
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Immunoblotting: 
Immobilon™-P nitrocellulose membrane (Millipore cooperation, USA) was washed for 3 
seconds in methanol and for 10 seconds in dH2O and incubated for at least 5 minutes in 
the blotting buffer. The gel and the Immobiline-P membrane were assembled in Mini 
Trans-Blot and blotting was run at 400 mA, 100 V for 1 hour. 
Immunodetection:  
Nitrocellulose membrane was washed at room temperature with gentle agitation in 25 ml 
PBS and in 25 ml blocking buffer for 10 minutes and 1 hour, respectively. The membrane 
was then incubated in Anti p53 antibody (Zymed, CA, USA) overnight at +4°C. The 
membrane was washed 3X for 5 minutes with 25 ml PBST with gentle agitation. Goat 
anti mouse IgG (Invitrogen) secondary antibody was added after having been diluted 
according to the manufacturer's recommendation into blocking buffer. The membrane 
was then incubated with gentle agitation for 1 hour. The membrane was then washed 
again 3X for 5 minutes in 25 ml PBST and 2X for 5 minutes in western wash buffer. 
Alkaline Phosphatase detection reaction: 
Detection of secondary antibody: alkaline phosphate (using CDP-Star). 
6 ml CDP star assay buffer and 12 µl CDP star were added to the membrane and shaked 
manually. The membrane was wrapped in plastic foil and sealed properly so it does not 
dry. Then the sealed membrane was wrapped in aluminum film and kept in darkness at 
room temperature for 30 minutes. A western blotting image was then taken by exposing 
the membrane in Lumi-Imager F1. 
Immunoprecipitation: 
In order to isolate protein partners of p53 and study the protein-protein interaction, 
immunoprecipitation using antibodies against V5 epitope was performed. 
IP followed by SDS-PAGE immunoblotting, 2D gel etc., is routinely used in a variety of 
applications to determine the molecular weights of protein antigens, to study protein-
protein interactions, to determine specific enzymatic activity, to monitor protein post-
translational modifications and to determine the presence and quantity of proteins. The IP 
technique also enables the detection of rare proteins which otherwise would be difficult 
to detect since they can be concentrated up to 10,000-fold by Immunoprecipitation (32).  
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In the IP method, the protein(s) from the cell or tissue homogenate is precipitated in an 
appropriate lysis buffer by means of an immune complex which includes the antigen 
protein (here: p53 and its partners), primary antibody (V5 antibody) and Protein G- (or 
A-, or L)-agarose conjugate, Figure 16, (32). 
 
Figure 16:  Schematic representation of the principle of Immunoprecipitation. An antibody is 
added to a mixture of proteins and binds specifically to its antigen. Antibody-antigen complex is 
absorbed from solution through the addition of an immobilized antibody binding protein such as 
Protein A-Sepharose beads (or protein G) (third panel). Upon centrifugation, the antibody-antigen 
complex is brought down in the pellet (fourth panel). Figure is adapted from Molecular Station 
website http://www.molecularstation.com (33). 
 
Experimental steps of immunoprecipitation: 
50µl of -G Sepharose™ resin slurry in lysis buffer (containing 2,5µl/ml protease inhibitor 
cocktail) was added per 1 ml of supernatant to pre-clear cell-lysates. The mixture was 
incubated at 4°C with continuous rocking for 1 hour and then centrifuged at the same 
temperature. 
1.5 µg (typically, 1.5 µl) of Anti-V5-HRP Antibodies and 50 µl of the Protein-G 
Sepharose™ resin slurry were added to the supernatant and rocked overnight at 4°C. The 
mixture was centrifuged for 1 minute at 10000g at 4°C and the resin slurry was washed 
5X in pre-chilled lysis buffer containing 2,5µL/ml protease-inhibitor. The beads were 
then resuspended in sample application buffer and then centrifuged again under the same 
conditions (10000 g at 4°C for 1 minute). The supernatant was stored at -80°C. 
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Two Dimensional Gel Electrophoresis:  
Proteomics: 
Proteomics, the large-scale analysis of proteins is contributing greatly to our 
understanding of gene function in the post-genomic era. Proteomics is used for 
identifying and quantifying expressed proteins in cells, organisms or fluids. It is also a 
mean for localizing proteins in the cell and detecting protein modifications and 
interactions (34). 
High-resolution two dimensional polyacrylamide gel electrophoresis (2D-PAGE or 2D-
gels) is a powerful technique for analyzing protein composition of a cell, tissue and 
fluids, as well as for studying changes in global patterns of gene expression elicited by a 
wide array of effectors. The method has become increasingly important after the 
development of identifying the individual spots on the gel by mass spectrometry analysis 
(35). 
The 2D-gels separate polypeptides on the basis of their ioselectric points (pI) in the first 
dimension and the molecular weights in the second dimension. Adding ampholytes to an 
acrylamide strip generates the IEF (isoelectric focusing) gradient. The ampholytes are a 
mixture of amphoteric species with a range of pH values. This IEF separates protein 
based on their ioselectric point (pI) and is accomplished by the pH gradient established in 
the acrylamide. Proteins migrate through the pH gradient until they reach the pH at which 
their net charge is zero whereupon the protein stops and focuses at that point. The second 
dimension separates the proteins on the basis of molecular weight in an SDS gel. This is 
accomplished by laying the strips (from 1 dimension) on top of a slab-type SDS-
polyacrylamide gel. Prior to this, the strips were equilibrated in equilibration buffers, 
Table 11. Most of the proteins will dissociate into their polypeptide subunits and will be 
coated with SDS. This protein-SDS complex (mass ratio 1:14) consists of the 
hydrocarbon chains of the detergent in a rigid association with the polypeptide chain 
leaving negatively charged sulfate ions of the detergent (SDS) exposed to the aqueous 
medium. The native charge of the polypeptide is overcome and the complex migrates as 
an anion. The rate of the migration correlates with the molecular weight of the protein 
(36) . 
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Experimental steps of 2-DE: 
Sample preparation: 
Concentrating the samples: 
When the total protein concentration was low, the following method was used to 
concentrate the samples: 
Five volumes of acetone was added to each diluted sample and incubated at room 
temperature for 30 minutes. The samples were then centrifuged for 15 minutes at 6400 x 
g (corresponds 6000 rpm in BS4402/A HERAEUS SEPATECH) at 4°C. The supernatant 
was removed and the samples were rehydrated using 125 µl or 250 µl sample application 
buffer, Table 11. 
1 µl IPG buffer and 1,3 µl of 1,5 M DTT were added to each 125 µl of sample 
application buffer. The samples were then loaded on the strips ceramic holders and the 
strips were placed upon them. Liquid paraffin was used to cover the strips. First and 
second dimensions of electrophoresis were run according to Tables 14 and 15, 
respectively. 
We have increased the concentration of total protein gradually until we could get some 
better results. The amount of total protein run on a gel was 450 µg. This amount was 
decided after several pilot experiments. In immunoprecipited proteins experiments, we 
used 2 mg total protein for immunoprecipitation. Of the immunoprecipitation final 
product, we tried various volumes to run on a gel and after pilot experiments we found 
that 45 µl was the minimal volume that could show some faint spots when the gel is 
stained with SYPRO Ruby.  
 
The first-dimension: Isoelectric focusing (IEF): 
IPGphor (Pharmacia Biotech) was used for 1st dimension Electrophoresis. 
Table 14: Shows the conditions of first dimension separating, S1 is rehydration step 
 S1 S2 S3 S4 S5 S6 S7 Total 
30 V 300 V 1000 V 2500 V 5000 V 5000 V - 7 cm 
strips 10:00 hrs 1:00 hr 1:00 hr 1:00 hr 1:00 hr 3:00 hrs - 
20000 
vhr 
30 V 300 V 600 V 1000 V 4000 V 8000 V 8000 V 13 cm 
strips 10:00 hrs 1:00 hr 1:00 hr 0:30 hr 2:00 hrs 2:00 hr 4:00 hr 
40000 
vhr 
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When the first dimension is complete, the strips were equilibrated equilibration in buffers 
1 and 2, for 15 minutes, Table 11. 
The second dimension: SDS-PAGE electrophoresis: 
PowerPac HC™ (Bio-Rad) was used for 2nd dimension. 
The gels were made and formed in our labs, Table 11. The strips were placed on the tops 
of the gels. One or two strips per gel for 13 or 7 cm strips, respectively. The tops of the 
gels were sealed by 1 ml 5% Agarose and the gels were run under the conditions shown 
in Table 15. 
Table 15: Shows the conditions of second dimension separating 
 Volt Amp Watt Hours 
7 cm strips 250 0,16 150 2-2,5 
13 cm strips 250 0,32 150 3-4 
 
Protein spot detection: 
Protein spots can be resolved on 2D gels visualized using a variety of methods, including 
Coomassie brilliant blue staining and SYPRO Ruby. In this experiment we mainly used 
Coomassie brilliant blue staining. SimplyBlue® Safe Stain from Invitrogen. Sometimes 
we used SYPRO Ruby (Bio-Rad) staining for immunoprecipitated proteins in an attempt 
to show the spots resulting from low protein concentration. SYPRO Ruby is known to be 
30 times more sensitive than Coomassie blue. Staining was done according to the 
instruction of the manufacturer. 
 
Gel Analysis: 
Protein profiles for the empty vector, wild type and mutant p53 were scanned and 
quantified to search for differences in expression, such as change in the level of protein 
expression or appearing/disappearing of peptides/proteins. The current 2D PAGE 
techniques make it possible to visualize maximum about 4000-5000 proteins. This 
number is only a fraction of the number presented in any eukaryotic cell. Some proteins 
are also not detected, since they are not resolved by the pH gradient, because they are too 
basic or too acidic. Solubilization problems may prevent them for entering the first 
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dimension, because they precipitate and streak the run or because of limitations in the 
sensitivity of current detection methods.  
PDQuest software from Bio-Rad was used to analyze the protein spots and compare the 
spots in different gels for the different p53 alleles. Spots were studied and 12 
differentially expressed spots were selected, excised from the gels and sent to further 
analysis by mass spectrophotometry. 
Mass Spectrometry: 
Matrix-assisted lasers desorption/ionization time-of-flight mass spectrometer (MALDI 
TOF MS) was performed. 
Mass spectrometry (MS) is an extremely useful tool in many fields of chemistry and 
biochemistry. The particular nature of MS that was employed in this experiment involves 
the trypsinization of the sample protein into many smaller fragments, then a comparison 
of the mass spectrometry spectra of these fragments with those known peptides in NCBI 
database http://www.ncbi.nlm.nih.gov/.  
MS employed in situ trypsinization of the isolated protein spots in gel into smaller 
peptide-fragments. 
GC 8000Top, CEINSTRUMENTS, ThermoQuest, Italy MS was used in the Faculty of 
Pharmacy, University of Tromsø. Generated data were investigated further using NCBI 
database. 
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Results 
Site-Directed Mutagenesis (SDM): 
Site-directed mutagenesis of p53 WT to generate P53-R249S mutation: 
Agarose gel Electrophoresis (0.8%) was run for PCR product in order to check that PCR 
mutagenesis has generated DNA product and to verify that the product is of the expected 
size before DNA sequence analysis. The PCR based SDM products revealed a band of 
the expected size of the linear pGene/V5-His-p53 vector DNA, Figure 17. 
 
 
Figure 17: Agarose gel of R249S SDM PCR products, WT plasmid preparation product, pSwitch 
and pGene (EV). The gel shows bands of the expected size of the pGene/V5-His-p53 vectors, P 
Switch and empty pGene/V5-His vector 
 
 
DNA Sequence of pGene/V5-His-p53 (mutants) vectors: 
In order to confirm that the targeted mutations were successfully introduced, the p53 gene 
cloned in pGene/V5-His vector was sequenced using Sanger chain terminating 
sequencing method and using Big Dye protocol. The results of the DNA sequence 
analysis confirmed the presence of the introduced mutation in p53 coding sequence. Only 
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one mutation (R249S) will be presented here as an example of how the mutations for the 
other p53 mutant (R273H) presented in this work was made. 
The sequences analysis obtained were aligned and blasted against WT p53 using BLAST 
2 SEQUENCES in NCBI blast engine: 
http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi. This engine offers the possibility 
to compare two sequences. The alignment revealed the targeted mismatching at the 
correct place, Figure 18. Full sequence analysis of R249S is presented in appendix 3. 
 
 
Figure 18: Alignment of the R249S sequence (forward primer) (Subject) with the WT p53 
sequence (Query). (BLAST 2 SEQUENCES RESULTS VERSION BLASTN 2.2.14) 
 
Western blot: 
Saos-2 cells were chozen to establish the cell lines because these cells are p53 null. 
Permanent cell lines were established expressing wild type p53, mutant p53 or non-p53 
(EV). This expression is controlled through a mifepristone induction system. The 
selection agents are Zeocine and Hygromycine at concentration of 20 µg/ml of both 
drugs. Total protein extracts, both induced with mifepristone and non-induced, were 
checked for the presence of p53. Western blotting and Coomassie staining of SDS-PAGE 
gel were done. Using monoclonal Anti p53 antibody, several bands were observed. The 
p53-V5 fusion protein has theoretical molecular weight of 48 kDa. The additional bands 
could be as a result of cross reactivity. As expected and as shown in figure 19 A and B, 
samples of total proteins isolated from induced p53 showed bands in the three p53 alleles: 
WT, R249S and R273H (Lanes 3, 5 and 6, respectively). No bands could be detected in 
the non-induced WT (Lane 7) and neither induced nor non-induced EV (Lanes 4 and 8, 
respectively). Two bands appear in the non-induced R249S (Lane 9) and non-induced 
R273H (Lane 10) indicating some leakage in the p53 expression in our system. However, 
the Western experiment needs to be optimized by changing the type of antibody as well 
as the concentration and also the concentration of total protein used. 
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Figure 19: Western blot analysis of p53 expression in Saos-2 cells. A: Full image. B: Samples of 
total proteins isolated from induced p53 showed bands in the three p53 alleles: WT, R249S and 
R273H (Lanes 3,5 and 6, respectively). No bands could be detected in the non-induced WT (Lane 
7) and neither induced nor non-induced EV (Lanes 4 and 8, respectively). Two bands appear in 
the non-induced R249S (Lane 9) and non-induced R273H (Lane 10) indicating some leakage in 
the p53 expression in our system. Lane 1 Blue Plus 2 Prestained standard. Lane 2 Biotinylated 
standard did not work.  
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2D- Gel Electrophoresis 
Total proteins expressed under the conditions described earlier, were isolated from the 
constructed stable cell lines that are based on Saos-2 cells, but contain different alleles of 
p53 gene (WT: Wild Type, EV: Empty Vector, and Mutation R249S or R273H). These 
engineered cell lines were grown in the presence of Hygromycine and Zeocine. 
Hygromycine is selection agent for the pSwitch regulatory plasmid and Zeocin is 
selection agent for the pGene/V5-His-p53. The expression of the different p53 alleles was 
induced by Mifepristone 1 x 10-8 M for 24 hours. 
Aliquots of 450 µg of total protein were used for each gel. This amount was decided after 
several pilot experiments. As for the immunoprecipitated protein, the gels presented here 
were run using 45 µL of the immunoprecipitation proteins resulting from 2 mg total 
protein prior to the IP.  
Immunoprecipitated p53- V5 fusion protein: 
P53 and its partner proteins were isolated from the total protein using anti V5 antibody. 
Figure 20 shows 2D gel resulted from running 45 µL immunoprecipitated R249S and 
R273H mutant p53-V5. Two 7 cm IPG strips were applied on the same gel, which was 
stained with Coomassie Blue. No spots were detected. 
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Figure 20: Immunoprecipitated p53-V5 fusion protein as precipitated by anti V5 antibody and 
run on 2D gel and stained with Coomassie Blue. The gel showed no spots.  
 
Figures 21 and 22 show 2D gel results using the 45 µl of the IP protein isolated from 2 
mg total protein. Gels were stained with SYPRO Ruby, which is known to be 30 times 
more sensitive than Coomassie Blue. Some faint spots could be detected. However, the 
results are still unreliable since it has not been repeated and the spots were not as 
differential as expected.  This could reflect problems with the IP procedures optimization 
or the type of antibody used. 
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Figure 21: 2D gel of immunoprecipitated p53-V5 protein (WT and R249S) with anti V5 antibody 
and stained with SYPRO Ruby. Arrows indicate few faint spots. Spots are poorly separated and 
the quality of the 2D gel makes it not possible to conclude any differences in the expression 
patterns between the two p53 variants shown here. 
 
M. Belal Al-Jabri, 2006  Results 
 
 43  
 
Figure 22: The same 2D gel of immunoprecipitated p53-V5 protein (WT and R249S) with anti 
V5 antibody and stained with SYPRO Ruby, inverted colors. Arrows indicate the same spots 
marked in Figure 21. 
 
Limited attempts to increase the intensity of the spots by increasing the amount of protein 
samples loaded on the gels and the amount of the protein used for immunoprecipitation, 
were not successful. Due to these IP results and limited time available for this study, we 
concentrated on the total protein analysis by 2D gel electrophoresis rather than 
immunoprecipitated protein from the different p53 variants as compared to the empty 
vector and the WT. 
Total proteins: 
Total protein sample of 450 µg from each corresponding cell line were loaded on 13 cm 
strips holders. The 2D gel electrophoresis was run according to the criteria mentioned in 
Materials and Methods section. The Coomassie Blue staining of 2D gel separations of the 
different p53 types extracts indicated some differences in the resolved proteins spots. The 
expression patterns of the different samples were similar but not identical.  
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In this experiment two gels for each p53 variant were run at the same time and 
conditions. Figure 23: A, B, C, and D shows one raw 2D-Gel for each p53 allele.  
Figure 23: Raw 2D gels of total proteins isolated from Saos-2 cells expressing different p53 
variants. A: Wild Type, B: Empty Vector, C: R249S mutant, D: R273H mutant 
 
The gels were analyzed and the spots were annotated using PDQuest software (Bio-Rad). 
Twelve protein spots were selected to be isolated and sent to MS analysis because they 
represented differentially expressed proteins. Figure 24 shows the locations of all the 
spots on the master gel and the corresponding locations on the appropriate gels. Table 16, 
presents the expression status of the selected spots in the different p53 variants.  
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Figure 24: The 2D gel electrophoresis results for total protein from Saos-2 expressing different 
p53 variants. A: Wild Type, B: Empty Vector, C: R249S mutant, D: R273H mutant. Numbers 
indicate the selected differentially expressed spots. Master gel (E) is shown in Gaussian form 
while all other gels are in filtered forms. 
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Table 16: The selected differentially expressed spots and the expression status of them 









1 1702 WT WT, 
R273H 
EV, R249S R273H WT 
2 5502 R273
H 
WT, R273H, EV R249S WT R273H, EV, 
3 2503 WT WT EV, R249S, 
R273H 
 WT 
4 4502 R249S All types, but at 
variable relative 
concentrations 




WT, R273H EV, R249S WT R273H 
6 6403 R249S WT, R249S EV, R273H WT R249S 
7 5805 EV All types, but at 
variable relative 
concentrations 




All types, but at 
variable relative 
concentrations 
 WT EV, R249S, 
R273H 
9 7102 R249S WT, EV, R249S R273H  WT,EV, R249S
10 6001 R249S EV, R249S, 
R273H 




R273H, R249S WT, EV  R273H, R249S 
12 6401 R273
H 
All types, but at 
variable relative 
concentrations 
 WT EV, R249S, 
R273H 
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MS results of the selected Protein spots: 
The MS results could specify 8 previously known and annotated proteins, while it failed 
to identify the spots numbers 2,4,6 and 7 therefore these spots are addressed further in 
this study, but these spots will be subjected again for MS analysis. Table 17 summarizes 
the MS results of the spot/protein identification.  
 





p53 status of 
the gel 
Identified Protein  
1 gi|190384 WT Prolyl 4-hydroxylase beta-subunit [Homo sapiens]
 
2 - R273H No significant hits 
3 gi|37852 WT Vimentin [Homo sapiens] 
4 - R249S No significant hits 
5 gi|28595 R273H Aldolase A protein [Homo sapiens] 
6 - R249S No significant hits 
7 - EV No significant hits 
8 gi|17389815 R273H Triosephosphate isomerase 1 (TIM) [Homo 
sapiens] 
9 gi|179780 R249S Carbonic Anhydrase II [Homo sapiens] 
10 gi|54855 R249S Triosephosphate isomerase [Mus musculus] 
11 gi|13325287 R273H Enolase 1 [Homo sapiens] 
12 gi|693933 R273H 2-phosphopyruvate-hydratase alpha-enolase; 
carbonate dehydratase [Homo sapiens] 
 
 
The 2D gel results represent two gels of the total isolated protein from cells expressing 
each of the p53 variant. Although we have delivered twelve spots for MS analysis, only 
eight spots gave protein identification. Therefore in this thesis, only the spots with 
identified proteins are discussed further. The spots with poor MS identification are spots 
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2, 4, 6 and 7, Table 17. Analysis of the identified spots from Mass Spectrometry 
including amino acid sequence and coding sequence is shown in Appendix no. 4. 
 In the MS analysis, only the first hit which constituting the most significant probability 
are analyzed further in details while the next three hits, if any, are only listed and can be 
searched in NCBI protein database. 
 
Spot No. 1: 
This protein spot is overexpressed in WT, but is not expressed in EV, R249S. It is only 
underexpressed in R273H. This protein spot was cut from the WT gel.  
The MS Result for this protein spot identified it as prolyl 4-hydroxylase beta-subunit 
[Homo sapiens]. This enzyme has a central role in the biosynthesis of collagens.  
Figure 25 shows the different expressions of the corresponding spot in the different gels.  
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Figure 25: Shows spot no.1 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed while the 
circles indicate that the spot is not expressed. Spot 1 is overexpressed in WT (A2 and to a less 
extent in A1), under-expressed in R273H (D1 and more under-expressed in D2) and not 
expressed in other types. Every column in the graph in the upper left corner of the gel A1 
represents the spot in one of the gels. The colour of the column matches the colour of the gel 
name. The heights of the columns reflect the quantity of the protein and missed columns reflect 
non-expressed spots in the corresponding gels. 
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Spot No. 3: 
This spot is overexpressed in WT, from which it was cut, while it is not expressed in EV, 
R249S, and R273H. The MS Result for this protein spot identified it as vimentin [Homo 
sapiens]. Vimentin is the major structural component of intermediate filaments in cells of 
mesenchymal origin, e.g. fibroblasts and endothelial cells (37). Figure 26, shows the 
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Figure 26: Shows spot no.3 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed (WT: A1 and 
A2) while circles indicate that the spot is not expressed (the rest of the gels). Every column in the 
graph shown in gel A1 represents the spot in one of the gels. The color of the column matches the 
color of the gel name. The heights of the columns reflect the quantity of the protein and missed 
columns reflect non-expressed spots in the corresponding gels. 
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Spot no. 5: 
This spot is expressed in WT and R273H, from which it was cut, while it is not expressed 
in EV and R249S. The MS Result for this protein spot identified it as Aldolase A 
protein [Homo sapiens]. Aldolase plays an important role in glucose metabolism. 
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Figure 27: Shows spot no. 5 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed (WT: A1 and 
A2, R273H: D1 and D2) while circles indicate that the spot is not expressed (EV: B1 and B2, 
R249S: C1 and C2). Every column in the graph shown in gel A1 represents the spot in one of the 
gels. The color of the column matches the color of the gel name. The heights of the columns 
reflect the quantity of the protein and missed columns reflect non-expressed spots in the 
corresponding gels. 
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Spot no. 8:  
This spot is overexpressed in EV, R249S and R273H from which it was cut, while it is 
underexpressed in WT. The MS Result for this protein spot identified it as 
Triosephosphate isomerase 1 [Homo sapiens]. Triosephosphate isomerase (TIM) is 
involved in glycolysis, gluconeogenesis and triglyceride synthesis (38). Figure 28 shows 
the different expressions of this protein spot in the different gels. 
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Figure 28: Shows spot no. 8 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed in all gels. The 
lower part of the gel C1 does not show all the expected spots as the gel C2 of the same type does. 
Every column in the graph shown in gel A1 represents the spot in one of the gels. The color of the 
column matches the color of the gel name. The heights of the columns reflect the quantity of the 
protein in the corresponding gels. The first two columns from right represent the spot in gels A1 
and A2 and show that it is considerably underexpresses in wild type. 
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Spot no. 9: 
This spot is overexpressed in WT, EV and R249S from which it was cut while it is 
missed in R273H. The MS Result for this protein spot identified it as Carbonic 
anhydrase II [Homo sapiens]. This enzyme catalyzes the reversible hydration of carbon 
dioxide and participates in various biological processes. Figure 29 shows the different 
expressions of this protein spot in the different gels. 
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Figure 29: Shows spot no.9 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed while circles 
indicate that the spot is not expressed. The lower part of the gel C1 does not show all the expected 
spots as the gel C2 of the same type does. Every column in the graph shown in gel A1 represents 
the spot in one of the gels. The color of the column matches the color of the gel name. The 
heights of the column reflect the quantity of the protein and missed columns reflect non-
expressed spots in the corresponding gels.  
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 Spot no. 10:  
This spot is overexpressed in EV, R273H and R249S from which it was cut, while it is 
not expressed in WT.  
The MS Result for this protein spot identified it as triosephosphate isomerase [Mus 
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Figur 30: Shows spot no.10 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed while circles 
indicate that the spot is not expressed. The lower part of the gel C1does not show all the expected 
spots as the gel C2 of the same type does. Every column in the graph shown in gel B1 represents 
the spot in one of the gels. The color of the column matches the color of the gel name. The 
heights of the columns reflect the quantity of the protein and missed columns reflect non-
expressed spots in the corresponding gels 
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Spot no. 11: 
This spot is expressed only in R273H from which it was cut while it is not expressed in 
WT, EV and R249S. The MS Result for this protein spot identified it as Enolase 1 
[Homo sapiens]. This enzyme is involved in glycolysis. Figure 31 shows the different 
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Figure 31: Shows spot no.11 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed while circles 
indicate that the spot is not expressed. Every column in the graph in gel C1 represents the spot in 
one of the gels. The color of the column matches the color of the gel name. The heights of the 
columns reflect the quantity of the protein and missed columns reflect non-expressed spots in the 
corresponding gels. 
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Spot No. 12:  
This spot is overexpressed in EV, R249S and R273H from which it was cut, while it is 
underexpressed in WT.  
The MS Result for this protein spot identified it as 2-phosphopyruvate-hydratase; 
alpha-enolase; carbonate dehydratase [Homo sapiens]. This enzyme is involved in 
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Figure 32: Shows spot no.12 in the different p53 variants’ gels. A1 and A2: WT, B1 and B2: EV, 
C1 and C2: R249S, D1 and D2: R273H. Squares indicate that the spot is observed in all gels. 
Every column in the graph shown in gel A1 represents the spot in one of the gels. The color of the 
column matches the color of the gel name. The heights of the columns reflect the quantity of the 
protein in the corresponding gels. This spot is underexpressed in WT compared to EV and 
mutants. Gel C1 does not show the spot as strong as it appears in the gel C2 of the same type.   
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Discussion 
Abnormalities of the p53 tumor suppressor gene are among the most frequent molecular 
events in human and animal Neoplasia (39). Mutations in p53 have been observed in over 
60% of all human cancers (4).The current version (October 2006) of IARC database 
(R11) contains 23,544 p53 somatic mutations (40). It is now accepted that the 
inactivation of this gene, as a result of mutation, is a key step in neoplastic transformation 
and progression (41). The tumor suppressor activity of p53 results from its ability to 
transcriptionally activate and repress a wide variety of target genes whose products in 
turn regulate among other things: cell cycle arrest, DNA repair, apoptosis, and 
suppression of angiogenesis (27). The p53 tumor suppressor activity is also a result of 
p53 involvement in cellular functions by protein-protein interactions (28). Functional 
diversity depends on the association with a large subset of partner proteins, which 
dictates the type of activity and corresponding selectivity (28).  
In this study we have analyzed changes in protein expression in Saos-2 cells in the 
absence of p53 and in presence of a cancer causing p53 mutations. The total protein 
expression patterns in Saos-2 cells containing wild type p53, R249S or R273H in addition 
to cells with no p53 copy were compared. These two mutations, R249S and R273H, are 
in the DNA binding domain of p53 and are involved mainly in liver cancer and colon 
cancer, respectively. Differential gene expression of normal and cancer causing p53 
mutations will help in establishing biomarkers that can be used in diagnosis, prognosis 
and therapy of relevant cancers. 
Mutagenesis: 
Agarose gel electrophoresis of site-directed mutagenesis PCR products indicated product 
of the expected size suggesting that the PCR was successful as was later confirmed by 
DNA sequence analysis, Figure 17. The PSwitch plasmid is 7.3 kb while the pGene/V5-
His vector (EV) is 4.6 kb. Cloning WT or mutant p53 into the pGene/V5-His vector 
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Establishing a stable inducible p53 cell lines: 
One of the major functions of p53 is to induce cell apoptosis, it becomes unlikely to 
create a stably transfected cell line with a constitutive expression of p53 (3). Therefore 
we have created four stable cell lines with inducible p53 expression for WT, EV, R273H 
and R249S. Additional advantages to engineered cell lines with inducible p53 expression 
are the relative homogeneity among cells in comparison to biopsies from patients with 
different ages and sex. Moreover, all engineered cells would express p53, albeit with 
different levels, while tumors often contain other cells that would interfere with gene 
expression profiling experiments.  
Xu and El-Gewely, 2002 and Xu, 2003 using cells with transient gene expression gave 
good results that were validated, but the transfection had to be repeated for every 
experiment since p53 expression was constitutive. Also we wanted to eliminate any 
contribution of cells that do not contain a p53 gene copy in a transient gene expression 
experiments since transfection is never any close to 100%. Therefore permanent 
transfection was made and permanent inducible cell line was established. The inducible 
p53 cell line Saos-2/p53, wild Type or mutant, was derived by cloning human p53 cDNA 
into the expression vector pGene/V5-His (Invitrogen) to generate the plasmid pGene/V5-
His-p53. pGene/V5-His-p53 was then co-transfected with the plasmid pSwitch 
(Invitrogen), which allows control of gene expression. This means that the gene will be 
expressed in a tightly and inducible manner. We added mifepristone for only 24 hours 
before isolating total protein in order to minimize the loss of cells by apoptosis. 
The bands on the western blotting gel shown in Figure 19 A and B represent p53 fusion 
protein which has theoretical molecular weight of 48 kDa. However, and probably due to 
post translational modification, the protein looks to have higher MW on the WB gel. 
Total proteins with induced p53 variants exhibited bands in lanes 3 (WT), 5 (R249S) and 
6 (R273H), but not in lane 4 (EV). This confirms that p53 is expressed in these three cell 
lines with pGene/V5-His-p53, but not expressed in the cell line with pGene only (empty 
vector). Similarly, no p53- band can be seen in lanes 7 and 8 that contain total proteins 
from non-induced WT p53 and EV, respectively. The Saos-2/wt p53, Saos-2/R249S and 
Saos-2/R273H inducible cell lines expressed p53 when induced with the inducer 
mifepristone. Theoretically, p53 should not be expressed until the mifepristone is added. 
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However, the system seems to have some leakage in p53 expression and the bands 
appeared in both Saos-2/R249S and Saos-2/R273H cell lines indicate a p53 expression 
without mifepristone induction indicating either leakage in the system or cross reactivity. 
An interpretation of this leakage might be a spontaneous stimulation of unknown reason 
of one of the promoters either on pSwitch or pGene/V5-His plasmids. 
Although the results of our western blotting were encouraging, the validation of our 
established cell lines needs to be optimized by changing the type of the antibody as well 
as the concentration of total proteins used. This could not be performed because of the 
limited time available to complete this study. 
 
Study of p53 partners: 
It was aimed to isolate protein partners with affinity purifications using antibodies against 
V5 epitope that was previously cloned in-frame with p53 gene. For unclear reasons, the 
2D gels of immunoprecipitated p53 and its partner proteins were not successful. Because 
the immunoprecipitation did not work, the p53 partner protein study could not be done. 
This part of the study needs also to be optimized by changing one or more of the 
experiment elements. Using more protein for immunoprecipitation, loading more proteins 
in the 2D gels, using another antibody for the IP, or even trying another total protein 
isolation and immunoprecipitation protocols might lead to better results. 
The focus of the thesis is to study the difference in protein expression profile in Saos-2 
cells expressing WT p53 or mutated p53 and in the absence of p53.  
The 2D gels of total proteins showed similar, but not identical protein expression 
patterns. The twelve spots were chosen according to their different expressions in the 
different p53 variants, Table 16. Other differentially expressed proteins can be found in 
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P53 and angiogenesis: 
Spot no. 1: Prolyl 4-Hydroxylase beta-subunit [Homo sapiens]: 
The collagen prolyl 4-hydroxylases (P4-Hs), enzymes residing within the endoplasmic 
reticulum, have a central role in the biosynthesis of collagens. In addition, cytoplasmic 
P4-Hs play a critical role in the regulation of the hypoxia-inducible transcription factor 
HIF alpha (42). 
Prolyl 4-hydroxylase consists of two distinct polypeptides, the catalytically more 
important alpha-subunit and the beta-subunit, which is identical to the multifunctional 
enzyme protein disulphide isomerase (PDI). The enzyme appears to be assembled in vivo 
into an alpha 2 beta 2 tetramer from newly synthesized alpha-subunits associating with an 
endogenous pool of beta-subunits (43). 
Our results show that Prolyl 4-Hydroxylase β subunit is overexpressed in WT p53, not 
expressed in EV, R249S and underexpressed in R273H. This suggests that the β subunit 
might be transcriptionally activated by p53 just like α subunit (as mentioned below (44)) 
Thus, p53 might be one of the factors that control the expression of both subunits of 
prolyl 4-hydroxylase with the inhibition of angiogenesis as one result. 
It is important to consider the possible roles of PDI in the P4-H complex. However, at 
least one role for the β-subunit/PDI has been clearly demonstrated, namely that the C-
terminal -KDEL sequence of the β-subunit/PDI is required for retention of the P4-H 
complex within the ER lumen (45). The second role of β-subunit/PDI could be to provide 
a structural framework for binding and preserving native α-subunits in a catalytically 
active, non-aggregated conformation. In addition, there is some evidence to suggest that 
non-active site sequences of the β-subunit/PDI are involved with the α-subunit in forming 
parts of the P4-H catalytic sites (46). As PDI is generally accepted as being the in vivo 
catalyst of disulphide bond formation in proteins destined for export from the ER (47). It 
is also possible that a further function of β-subunit/PDI may be to catalyze the formation 
of intramolecular disulphide bonds in the α-subunit of P4-H (43). 
It has been reported that the P4-H play a role in inhibition of angiogenesis, and therefore 
makes it an important component in tumors suppression regulation. This because tumors 
do not grow larger than a few millimeters in size unless vascularized by the host (48). (In 
1998, Holmgren et al. (1998) showed that p53 acts as a tumor suppressor gene 
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independent of its anti-proliferative effects and by inhibiting angiogenesis, p53 can 
indirectly induce apoptosis in vivo, but not in vitro. Thus, p53-gene therapy which alters a 
tumors angiogenic potential, can revert tumors to a dormant phenotype (49). 
It has been recently reported that p53-mediates inhibition of angiogenesis through up-
regulation of a collagen prolyl hydroxylase (44). 
Recent evidence suggests that antiangiogenic therapy is sensitive to p53 status in tumors, 
implicating a role for p53 in the regulation of angiogenesis (44). Teodoro GJ et al. (2006) 
showed that p53 transcriptionally activates the α(II) collagen prolyl-4-hydroxylase (P4-
H) [α(II)PH] gene, resulting in the extracellular release of antiangiogenic fragments of 
collagen type 4 and 18 (44). The antiangiogenic fragments of several human collagens, 
including collagen 4 and 18, can inhibit endothelial cell proliferation either by inducing 
growth arrest or apoptosis (50). Although it is well established that C terminal collagen 
fragments have an antiangiogenic activity (51), their physiological role and connection to 
cellular growth pathways have not been elucidated (44). α(II)PH induction by p53 results 
in increased synthesis and secretion of full-length collagens, which are then 
proteolytically processed in the extracellular matrix to produce antiangiogenic peptides 
(44). Although this extracellular proteolytic processing occurs, at least to some extent, 
constitutively in the absence of p53, p53 expression greatly enhances the processing of 
full-length collagen 18 to endostatin. On the basis of these observations, Teodoro et al. 
(44) proposed that p53 activates a transcriptional program that increases synthesis and 
processing of collagen-derived antiangiogenic peptides. 
In an earlier study by Tsukamoto et al. (1999), PLC/PRF/5 hepatoma cells secreted an 
inhibitor of the proliferation of vascular endothelial cells, which was enhanced by p53-
gene transfer. Results of this study suggested that the production of this p53-inducible 
angiogenesis inhibitor is responsible, at least partly, for the regulation of angiogenesis in 
human hepatomas (52). 
α subunit is well studied while the full function of β subunit is still not completely 
known. Yet, as mentioned above, β subunit is important for α subunit and the whole P4-H 
complex to complete its catalytical activity.  
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P53 and intermediate filaments: 
Spot no. 3: Vimentin [Homo sapiens]: 
Vimentin is the major structural component of intermediate filaments in cells of 
mesenchymal origin, e.g. fibroblasts and endothelial cells (37). The intermediate filament 
framework is one of the three cytoskeletal systems in mammalian cells. Its well-spread 
filamentous structure from the nucleus to the plasma membrane is believed to provide 
protection against various mechanical stresses (53). The dynamic property in the 
intermediate filament system plays a fundamental role in mediating changes in cell shape, 
cell division and migration, signaling molecule distribution, and smooth muscle force 
development. Vimentin is the most abundant intermediate filament protein in various cell 
types (54-56). 
In our study the vimentin was expressed in WT but not expressed in any of the cells 
expressing p53 mutants or in the EV. According to the MS results, the sequence coverage 
was 11%, which, is relatively low and makes the MS analysis in more need for 
validation. With this restriction in mind, our results are not in accordance with the results 
reported in the literature and mentioned below although it still suggests that p53 may play 
a role in regulating vimentin expression. 
Eckes B. et al. (1998) reported that stiffness of vimentin-deficient fibroblasts was 
reduced by 40% in comparison to wild-type cells. Vimentin-deficient cells also displayed 
reduced mechanical stability, motility and directional migration towards different chemo-
attractive stimuli. Absence of a vimentin filament network does not impair basic cellular 
functions needed for growth in culture, but cells are mechanically less stable, and 
therefore they are impaired in all functions depending upon mechanical stability (57). 
In a study by Hu L. et al. (2004) overexpression of vimentin was significantly associated 
with hepatocellualar carcinoma (HCC) metastasis which strongly suggests that the 
overexpression of vimentin may play an important role in the metastasis of HCC (58). 
The poor prognosis of HCC has been associated with the recurrence and the intrahepatic 
metastasis (59). Another study reported that co-expression of vimentin and cytokeratin 
(CK) in breast cancer showed a more aggressive phenotype associated with poor 
prognosis as compared with keratin-high/vimentin-negative or keratin-low/vimentin-
positive tumors.  (60).  
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In a recent study, Kudo et al. (2006) established a spindle cell squamous carcinoma 
SCSC cell line from a primary tumor expressing cytokeratin and vimentin, indicating 
carcinosarcoma-like characters. The established SCSC cell line was spindle-shaped and 
showed identical immunohistochemical characters to those of primary tumor cells. 
Similar to the primary tumor, the cell line showed p53 overexpression and had p53 
mutation at another codon 132: AAG (lys)-->AAT (asp) (61). This suggests that p53 may 
play a role in the regulation of vimentin expression. 
 
P53 and glycolysis: 
Spots no. 5: Aldolase A, no.8: Triosephosphate isomerase 1 (TIM) [Homo sapiens], 
no.11: Enolase 1 [Homo sapiens] and no.12: alpha-enolase: 
The proteins identified in these spots are all involved in glucose metabolism and 
particularly in glycolysis, therefore they will be discussed together. 
Aldolase plays an important role in glucose metabolism (38). It catalyzes the aldol 
reaction where the substrate fructose 1,6-bisphosphate is broken down into 
glyceraldehyde 3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) (62). 
Aldolase becomes elevated in serum with malignant tumors, and isozyme A is 
predominant in serum (63).  
Triosephosphate isomerase (TIM) is a homodimeric enzyme catalyzing the 
interconversion of D-glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, and 
is involved in glycolysis, gluconeogenesis and triglyceride synthesis (38). 
Alpha-enolase (α-enolase) is involved in glycolysis and catalyzes the conversion of 2-
phosphoglycerate to phosphoenolpyruvate, which in turn is dephosphorylated into 
pyruvate to yield ATP (38).  
In fact enolase 1 (spot 11) and α-enolase (spot 12) seem to be isoforms or isozymes. 
Though they are referred to be synonyms of the same protein in some web sites together 
with other names as well like carbonate dehydratase and 2-phosphopyruvate-hydratase. 
(iHOP: Information Hyperlinked Over Protein http://www.ihop-
net.org/UniPub/iHOP/gs/87985.html and http://getentry.ddbj.nig.ac.jp/) in spite of having 
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two different GI identifying numbers on NCBI protein database where the Enolase 1 is 
named as : Enolase 1 (alpha).  
But by comparing the amino acid sequences and the coding sequences obtained from 
NCBI protein database of the proteins identified in spots 11 (enolase 1) and 12 (alpha-
enolase), we found that they are different only in one nucleotide and as a result in one 
amino acid which is the amino acid number 252 where phenylalanine is found in enolase 
1 instead of serine in α-enolase. Since the two proteins have the same theoretical pI value 
(7.01), it is expected to find them on the same vertical line on the 2DE. However, the two 
spots from which the samples were collected were clearly differentiated on the first 
dimension separation, Figure 24. They have similar molecular weights 47.1689 kDa 
(enolase 1) and 47.1088 kDa (alpha-enolase), which is in accordance with what we have 
on the 2D gel electrophoresis. This means that enolase1 and α-enolase are coded by the 
same gene and the difference in their forms is due to post-translational modifications. Or 
this difference could also be as a result of almost identical gene duplication, but with little 
mutations/changes. 
Our results show a clear difference in the protein expression patterns of these three 
proteins between cells with WT p53, null-p53 and mutant p53 suggesting a role of p53 in 
the metabolism of tumors particularly in glycolysis. This, to large extent, is supported by 
several studies.  
Triosephosphate isomerase I (TIM) (Spot no.8, Figure 28 results) and α enolase (Spot 
no.12, Figure 32 results) were clearly underexpressed in the WT compared to EV and 
both R273H and R249S mutants. The R249S mutation is known to be associated mainly 
with liver and lung cancers according to IARC. Yet, the sequence coverage of the protein 
identified from spot 8 (TIM) was 62%, which is considerably high and making this 
protein on the priority list to be validated. Similarly, α-enolase was overexpressed in all 
types, but underexpressed in WT however, the sequence coverage was (20%).  
Also, enolase 1 (Spot no.11, Figure 31 results) was overexpressed in both mutants, but no 
expression could be detected in WT or in EV. The sequence coverage in MS was 38%. 
These results can be explained that mutant p53 leads to increased expression of these 
important enzymes to facilitate glycolysis in tumor cells.  
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On the other hand, our results showed no expression of aldolase A (Spot no.5, Figure 27 
results) in EV and R249S while it was expressed in WT and R273H (overexpressed in 
one of its gels). The sequence coverage of the protein identified in spot 5 with the 
aldolase A was 21%.  
In contrast to normal cells, cancer cells have a high glycolytic rate and utilize anaerobic 
pathways to metabolize glucose and produce high levels of lactate even in the presence of 
oxygen (64;65). This metabolic shift to a higher rate of aerobic glycolysis is commonly 
referred to as the Warburg effect after the pioneer work of Warburg (1930). In part this is 
due to development of intratumoral regions of hypoxia, arising from disordered vascular 
development and flow (65). Because glycolysis produces energy (ATP) far less 
efficiently than aerobic respiration, tumor cells have a much higher rate of glucose uptake 
than normal cells (64). PET (positron emission tomography) has confirmed that the vast 
majority (>90%) of human primary and metastatic tumors demonstrate increased glucose 
uptake indicating abnormal metabolism. Furthermore, PET has been used to show a 
direct correlation between tumor aggressiveness and the rate of glucose consumption 
(66).  
The physiological significance of the Warburg effect has been controversial since its 
discovery over 80 years ago, and now there is renewed and vigorous interest in 
understanding the relationship between cancer and altered energy metabolism (64). A 
commonly held view is that constitutive upregulation of glycolysis is likely to be an 
adaptation to hypoxia that develops as tumor cells grow progressively further away from 
their blood supply (67). 
The shift from aerobic mitochondrial respiration to glycolysis in tumor cells could be the 
result of increased activity of glycolytic enzymes, decreased utilization of pyruvate by 
mitochondria, reduced capacity to transport cytosolic NADH into mitochondria through 
mitochondrial NADH/NAD+ shuttle pathways, impaired tricarboxylic cycle, or defects in 
respiration at various points in the electron transport chain (64). 
In a recent study, Matoba et al. (2006) showed that p53 modulates the balance between 
the utilization of respiratory and glycolytic pathways (68). They showed that oxygen 
consumption (a measure of aerobic respiration) was lower in a preparation of liver 
mitochondria from p53-deficient mice compared with wild-type mice. They identified 
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synthesis of Cytochrome c Oxidase 2 (SCO2) as the downstream mediator of this effect 
in mice and human cancer cell lines. SCO2 is critical for regulating the cytochrome c 
oxidase (COX) complex, the major site of oxygen utilization in the eukaryotic cell. 
Disruption of the SCO2 gene in human cancer cells with wild-type p53 recapitulated the 
metabolic switch toward glycolysis that is exhibited by p53-deficient cells. That SCO2 
couples p53 to mitochondrial respiration provides a possible explanation for the Warburg 
effect and offers new clues as to how p53 might affect aging and metabolism (68).  
P53 can also inhibit glycolysis through its transcriptional target, TIGAR, which lowers 
the levels of fructose 2,6-bisphosphate, a molecule that promotes glycolysis (69). 
Ktuse et al. (2006) has also supported a role of p53 in regulating aerobic respiration. 
They noted that loss of p53 results in decreased oxygen consumption and aerobic 
respiration and promotes a switch to glycolysis, thereby reducing endurance during 
physical exercise (70). 
In 2005 Jones et al. reported that inhibition of glycolysis by glucose withdrawal was 
shown to serve as a signal for the phosphorylation and activation of p53. 
They showed that proliferating mammalian cells have a cell-cycle checkpoint that 
responds to glucose availability. The glucose-dependent checkpoint occurs at the G1/S 
boundary and is regulated by AMP-activated protein kinase (AMPK). AMPK activation 
induces phosphorylation of p53 on serine 15, and this phosphorylation is required to 
initiate AMPK-dependent cell-cycle arrest. AMPK-induced p53 activation promotes 
cellular survival in response to glucose deprivation, and cells that have undergone a p53-
dependent metabolic arrest can rapidly reenter the cell cycle upon glucose restoration 
(71). 
A recent study on prostate cancer cells supports our findings that the expression of 
aldoalse A, TIM, and α-enolase are somehow controlled by p53 and glycolysis as a result. 
Van den Bemd et al. (2006) performed proteomic analysis in a prostate cancer xenograft 
model in which immune-incompetent nude mouse were inoculated with human prostate 
cancer cells. Van den Bemd et al. identified six human enzymes involved in glycolysis 
(fructose-bisphosphate aldolase A, triose-phosphate isomerase, glyceraldehyde-3-
phosphate dehydrogenase, α-enolase, and lactate dehydrogenases A and B) in the serum 
of the tumor-bearing mice (72). This study supports our findings that TIM and -enolase 
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were obviously overexpressed in mutant and null p53 cells compared to the WT p53 
cells. As a result, this supports the theory that p53 controls the expression of these crucial 
enzymes. 
Similar results in lung cancer were shown in another study by Nakanishi et al. (2006). 
They screened lung cancer for specific autoantibodies. Solubilized proteins from a cancer 
cell line (A549) were separated using 2D-Gel, followed by Western blotting (WB) 
analysis, in which the sera of individual patients were tested for primary antibodies. They 
identified eight proteins, α-enolase, inosine-5′-monophosphate dehydrogenase, aldehyde 
dehydrogenase, 3-phosphoglycerate dehydrogenase, 3-oxoacid CoA transferase, 
chaperonin, peroxiredoxin 6 and triosephosphate isomerase, which reacted with these 
antibodies in patients’ sera using MALDI-TOF/TOF. All eight antibodies were not 
detected in the sera derived from lung tuberculosis and healthy controls (73). 
In another interesting supportive study, Okano et al. (2006) investigated aberrant plasma 
proteins also in lung cancer by comparing the proteomic profiles of serum from lung 
cancer patients and from healthy volunteers. Mass spectrometric protein analysis 
identified among other proteins triosephosphate isomerase to be two fold higher in 
patients with lung cancer than in healthy volunteers (74). 
Similarly, it was reported that increased amounts of triosephosphate isomerase in urine or 
bladder tissue may be indicative of squamous metaplasia, squamous cell carcinoma, or 
other bladder injuries (75). 
Expression of α-enolase increased with tumor dedifferentiation and was significantly 
higher in poorly differentiated hepatocellular carcinoma HCC than in well-differentiated 
HCC. Expression of α-enolase also correlated positively with tumor size and venous 
invasion. This study suggested that α-enolase is one of the candidates for biomarkers for 
tumor progression that deserves further investigation in HCV-related HCC (76).These 
results  support our finding that α-enolase can be overexpressed in cancer. Yet, our 
results go further in showing that α-enolase is linked to p53 in cancer causing mutants 
such as R249S and R273H, but not WT 53.  
Aldolase A has been reported earlier to be elevated in malignant tumors (63). Yet, it has 
been suggested in a very early study to be used as biomarker for renal cell carcinoma 
(RCC) by Takashi et al. (1992). They reported that serum aldolase A is a useful 
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biomarker for monitoring the clinical course of patients with RCC (77). Also Aldolase A 
mRNA was noticed to be approximately 10-fold higher in liver biopsies from patients 
with hepatocellular carcinoma vs patients with chronic hepatitis C or cirrhosis, and 
healthy individuals (78). Our results suggest that this elevation might be controlled by 
p53. 
 
Spot no. 9: Carbonic Anhydrase I [Homo sapiens]: 
The growing α-carbonic anhydrase (CA) gene family includes 11 enzymatically active 
members that catalyze the reversible hydration of carbon dioxide: 
and participate in various biological processes, including 
respiration, bone resorption, renal acidification, gluconeogenesis, and formation of 
cerebrospinal fluid and gastric acid (79). The CA isozymes differ in their kinetic 
properties, their tissue distribution and subcellular localization, and their susceptibility to 
various inhibitors (79). Several CA isozymes (I and II) are expressed in the enterocytes of 
the normal intestine (80). However, two of them, CA IX and CA XII, have been linked to 
oncogenesis, and their overexpression has been observed in malignant tumor cells (79) 
(81) (82).  
Our results, Figure 29, show that carbonic anhydrase I was overexpressed in WT, EV and 
one gel of R249S but it was not expressed at all in R273H, which is known to be 
frequently associated with colorectal cancers according to IARC. The sequence coverage 
of this protein was 33%. These results are in accordance with a possible role of p53 in the 
decreased level of expression in colorectal cancers (presented below). However, for this 
protein being overexpressed in EV as in WT does not support the fact that this protein is 
controlled by p53. 
Kivela et al. (2001) reported that while the normal mucosa of the large intestine showed 
high expression for CA I and II, the intensity of the immunostaining for both isozymes 
decreased in benign lesions and was very weak in malignant tumors. While CA I and II 
are prominent in normal colorectal mucosa, where they play a role in regulation of pH 
homeostasis and water and ion transport, loss of expression of these cytoplasmic 
isozymes consistently accompanies progression to malignant transformation (79). 
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Chiang et al. (2002) studied the possible relationship between the expression of cytosolic 
carbonic anhydrase (I and II) and non-small cell lung cancer (NSCLC). Their results 
showed that the CA activity and protein expression were significantly decreased in both 
squamous cell carcinoma (SCC) and adenocarcinoma (AD). From this study, it was 
suggested that the reduction of CA I and CA II in both SCC and AD patients may 
promote tumor cell motility and contribute to tumor growth and metastasis (83). 
Also the majority of colorectal cancers do not express carbonic anhydrase isoenzyme I. 
The presence of any isoenzyme I-positive immunoreactive cancer cells may be associated 
with a more favorable outcome in colorectal cancer (84). 
Zhang et al. (1997) examined the global gene expression profiles of normal and 
cancerous human colonic epithelium. They reported a concomitant decrease of CA I and 
CA II mRNA levels in the cancerous epithelium (85). However, another study by Cole et 
al. (2000) showed a decrease in CA I protein expression only (86). 
 
Spot no. 10: Triosephosphate isomerase [Mus musculus]: 
This spot, Figure 30, was not of interest since it was not Homo sapiens’ protein. Besides, 
the covering sequence was low (9%) and does not give an extinctive presentation of the 
identified protein. However, this spot was very close to spot no 8 (Triosephosphate 
isomerase 1 (TIM) [Homo sapiens]), which means that it has a close MW and pI. So it 
could be an isoenzyme of the human enzyme and the identification of the mouse enzyme 
was artifact. Therefore this spot must be analyzed further later. 
Concluding notes: 
The association of specific proteins with cells that express different p53 variants and 
understanding the regulation of their expression will aid in determination of their 
potential role as biomarkers and/or as targets for therapeutic development for at least 
some cancers. Nevertheless, our results in general need to be validated thoroughly and by 
first running more 2D gels and then performing other validating methods. These methods 
would include Western blot with appropriate antibodies as well as isolating mRNA and 
designing appropriate specific primers for the mRNA for the corresponding protein and 
running RT-PCR. These two methods (RT-PCR and WB) are also quantitative. Moreover 
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microarray, which is also quantitative can be used with total isolated mRNA to discover 
any differential expression of downstream genes, at the transcriptional level, whether it 
include the above discussed protein spots or not. 
For the validation of the function of the discussed protein Spots (Tables 17 18), SiRNA 
against the identified genes can be made for experiments designed to validate the 
functional role of such proteins as related to cancer or a supporting role for p53. SiRNA 
is easier and less expensive than transgenic knock-out. 
 
Table 18: Summary of the high priority differentially expressed proteins among p53 different 
variants for validation. 
Spot 
number 
Identified Protein Expression 
1 Prolyl 4-hydroxylase beta-
subunit  
↑ WT, ↓ R273H. Not expressed: EV, 
R249S 
8 Triosephosphate isomerase 1 
(TIM)  
↑ EV, R249S, R273H. ↓ WT 
11 Enolase 1 ↑ R249S, R273H. Not expressed: WT, 
EV 
12 Alpha-enolase ↑ EV, R249S, R273H. ↓ WT  
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Appendices 
Appendix NO. 1 Human wild type p53 sequence: 
DEFINITION: Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) (TP53), mRNA. 
SOURCE      human 
ORGANISM    human 
COMMENT     Human wild type p53 
        1 atggaggagc cgcagtcaga tcctagcgtc gagccccctc tgagtcagga aacattttca  
       61 gacctatgga aactacttcc tgaaaacaac gttctgtccc ccttgccgtc ccaagcaatg  
      121 gatgatttga tgctgtcccc ggacgatatt gaacaatggt tcactgaaga cccaggtcca  
      181 gatgaagctc ccagaatgcc agaggctgct ccccccgtgg cccctgcacc agcagctcct  
      241 acaccggcgg cccctgcacc agccccctcc tggcccctgt catcttctgt cccttcccag  
      301 aaaacctacc agggcagcta cggtttccgt ctgggcttct tgcattctgg gacagccaag  
      361 tctgtgactt gcacgtactc ccctgccctc aacaagatgt tttgccaact ggccaagacc  
      421 tgccctgtgc agctgtgggt tgattccaca cccccgcccg gcacccgcgt ccgcgccatg  
      481 gccatctaca agcagtcaca gcacatgacg gaggttgtga ggcgctgccc ccaccatgag  
      541 cgctgctcag atagcgatgg tctggcccct cctcagcatc ttatccgagt ggaaggaaat  
      601 ttgcgtgtgg agtatttgga tgacagaaac acttttcgac atagtgtggt ggtgccctat  
      661 gagccgcctg aggttggctc tgactgtacc accatccact acaactacat gtgtaacagt  
      721 tcctgcatgg gcggcatgaa ccggaggccc atcctcacca tcatcacact ggaagactcc  
      781 agtggtaatc tactgggacg gaacagcttt gaggtgcgtg tttgtgcctg tcctgggaga  
      841 gaccggcgca cagaggaaga gaatctccgc aagaaagggg agcctcacca cgagctgccc  
      901 ccagggagca ctaagcgagc actgcccaac aacaccagct cctctcccca gccaaagaag  
      961 aaaccactgg atggagaata tttcaccctt cagatccgtg ggcgtgagcg cttcgagatg  
     1021 ttccgagagc tgaatgaggc cttggaactc aaggatgccc aggctgggaa ggagccaggg  
     1081 gggagcaggg ctcactccag ccacctgaag tccaaaaagg gtcagtctac ctcccgccat  
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BLACK:   pGene/V5-His B vector sequence 
BLUE:   p53 gene sequence 
RED:   primer sequence 
RED MARKED YELLOW:  Restriction enzyme site in the primers (HindIII and EcoRI) 
GREEN:   ATG = start codon to the p53 gene 
                    TGG = a stop (TGA) codon has been changed to a Trp (W)(TGG) 
codon  
Orange marked   His Tag 6xHis (CAT CAT CAC CAT CAC CAT) 
Plum marked:    Coding for the V5 Tag 
 
Studied mutants 
BLUE MARKED GREEN: agg = amino acid 249, R249S = AGG → AGC 
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Appendix NO.3 DNA Sequence analysis of R249S: 
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Appendix NO.4 Analysis from Mass Spectrometry of the identified spots: 
Spot 1 Analysis from Mass Spectrometry: 
Match to: gi|190384 Score: 389 
Prolyl 4-hydroxylase beta-subunit [Homo sapiens] 
Nominal mass (Mr): 57480. Calculated pI value: 4.76. 508 amino acids (AA). 
Taxonomy: Homo sapiens 
Accession in NCBI:gi|48735337 from Homo sapiens 
gi|20810352 from Homo sapiens 
gi|14790033 from Homo sapiens 
Sequence Coverage: 21% 
 
Amino Acid sequence of prolyl 4-hydroxylase beta-subunit [Homo sapiens]: 
Matched peptides shown in Bold Red 
     1 MLRRALLCLA VAALVRADAP EEEDHVLVLR KSNFAEALAA HKYLLVEFYA  
    51 PWCGHCKALA PEYAKAAGKL KAEGSEIRLA KVDATEESDL AQQYGVRGYP  
   101 TIKFFRNGDT ASPKEYTAGR EADDIVNWLK KRTGPAATTL PDGAAAESLV  
   151 ESSEVAVIGF FKDVESDSAK QFLQAAEAID DIPFGITSNS DVFSKYQLDK  
   201 DGVVLFKKFD EGRNNFEGEV TKENLLDFIK HNQLPLVIEF TEQTAPKIFG  
   251 GEIKTHILLF LPKSVSDYDG KLSNFKTAAE SFKGKILFIF IDSDHTDNQR  
   301 ILEFFGLKKE ECPAVRLITL EEEMTKYKPE SEELTAERIT EFCHRFLEGK  
   351 IKPHLMSQEL PEDWDKQPVK VLVGKNFEDV AFDEKKNVFV EFYAPWCGHC  
   401 KQLAPIWDKL GETYKDHENI VIAKMDSTAN EVEAVKVHSF PTLKFFPASA  
   451 DRTVIDYNGE RTLDGFKKFL ESGGQDGAGD DDDLEDLEEA EEPDMEEDDD  
   501 QKAVKDEL 
Coding sequence of prolyl 4-hydroxylase beta-subunit [Homo sapiens], Accession No. 
gi|190384: 
        1 atgctgcgcc gcgctctgct gtgcctggcc gtggccgccc tggtgcgcgc cgacgccccc 
       61 gaggaggagg accacgtcct ggtgctgcgg aaaagcaact tcgcggaggc gctggcggcc 
      121 cacaagtacc tgctggtgga gttctatgcc ccttggtgtg gccactgcaa ggctctggcc 
      181 cctgagtatg ccaaagccgc tgggaagctg aaggcagaag gttccgagat caggttggcc 
      241 aaggtggacg ccacggagga gtctgacctg gcccagcagt acggcgtgcg cggctatccc 
      301 accatcaagt tcttcaggaa tggagacacg gcttccccca aggaatatac agctggcaga 
      361 gaggctgatg acatcgtgaa ctggctgaag aagcgcacgg gcccggctgc caccaccctg 
      421 cctgacggcg cagctgcaga gtccttggtg gagtccagcg aggtggctgt catcggcttc 
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      481 ttcaaggacg tggagtcgga ctctgccaag cagtttttgc aggcagcaga ggccatcgat 
      541 gacataccat ttgggatcac ttccaacagt gacgtgttct ccaaatacca gctcgacaaa 
      601 gatggggttg tcctctttaa gaagtttgat gaaggccgga acaactttga aggggaggtc 
      661 accaaggaga acctgctgga ctttatcaaa cacaaccagc tgccccttgt catcgagttc 
      721 accgagcaga cagccccgaa gatttttgga ggtgaaatca agactcacat cctgctgttc 
      781 ttgcccaaga gtgtgtctga ctatgacggc aaactgagca acttcaaaac agcagccgag 
      841 agcttcaagg gcaagatcct gttcatcttc atcgacagcg accacaccga caaccagcgc 
      901 atcctcgagt tctttggcct gaagaaggaa gagtgcccgg ccgtgcgcct catcaccctg 
      961 gaggaggaga tgaccaagta caagcccgaa tcggaggagc tgacggcaga gaggatcaca 
     1021 gagttctgcc accgcttcct ggagggcaaa atcaagcccc acctgatgag ccaggagctg 
     1081 ccggaggact gggacaagca gcctgtcaag gtgcttgttg ggaagaactt tgaagacgtg 
     1141 gcttttgatg agaaaaaaaa cgtctttgtg gagttctatg ccccatggtg tggtcactgc 
     1201 aaacagttgg ctcccatttg ggataaactg ggagagacgt acaaggacca tgagaacatc 
     1261 gtcatcgcca agatggactc gactgccaac gaggtggagg ccgtcaaagt gcacagcttc 
     1321 cccacactca agttctttcc tgccagtgcc gacaggacgg tcattgatta caacggggaa 
     1381 cgcacgctgg atggttttaa gaaattcctg gagagcggtg gccaggatgg ggcaggggat 
     1441 gatgacgatc tcgaggacct ggaagaagca gaggagccag acatggagga agacgatgat 
     1501 cagaaagctg tgaaagatga actgtaa 
 
Spot 3 Analysis from Mass Spectrometry: 
Match to: gi|37852 Score: 213 
Vimentin [Homo sapiens] 
Nominal mass (Mr): 53710. Calculated pI value: 5.06. 466 AA. 
Taxonomy: Homo sapiens 
Sequence Coverage: 11% 
Amino Acid sequence of vimentin [Homo sapiens]: 
Matched peptides shown in Bold Red 
     1 MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR  
    51 SLYASSPGGV YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR  
   101 TNEKVELQEL NDRFANYIDK VRFLEQQNKI LLAELEQLKG QGKSRLGDLY  
   151 EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE  
   201 NTLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE EIQELQAQIQ  
   251 EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE  
   301 AANRNNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN  
   351 FAVEAANYQD TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY  
   401 RKLLEGEESR ISLPLPNFSS LNLRETNLDS LPLVDTHSKR TFLIKTVETR  
   451 DGQVINETSQ HHDDLE 
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Coding Sequence of vimentin [Homo sapiens]: Accession No. gi|37852: 
 1 atgtccacca ggtccgtgtc ctcgtcctcc taccgcagga tgttcggcgg cccgggcacc 
       61 gcgagccggc cgagctccag ccggagctac gtgactacgt ccacccgcac ctacagcctg 
      121 ggcagcgcgc tgcgccccag caccagccgc agcctctacg cctcgtcccc gggcggcgtg 
      181 tatgccacgc gctcctctgc cgtgcgcctg cggagcagcg tgcccggggt gcggctcctg 
      241 caggactcgg tggacttctc gctggccgac gccatcaaca ccgagttcaa gaacacccgc 
      301 accaacgaga aggtggagct gcaggagctg aatgaccgct tcgccaacta catcgacaag 
      361 gtgcgcttcc tggagcagca gaataagatc ctgctggccg agctcgagca gctcaagggc 
      421 caaggcaagt cgcgcctagg ggacctctac gaggaggaga tgcgggagct gcgccggcag 
      481 gtggaccagc taaccaacga caaagcccgc gtcgaggtgg agcgcgacaa cctggccgag 
      541 gacatcatgc gcctccggga gaaattgcag gaggagatgc ttcagagaga ggaagccgaa 
      601 aacaccctgc aatctttcag acaggatgtt gacaatgcgt ctctggcacg tcttgacctt 
      661 gaacgcaaag tggaatcttt gcaagaagag attgcctttt tgaagaaact ccacgaagag 
      721 gaaatccagg agctgcaggc tcagattcag gaacagcatg tccaaatcga tgtggatgtt 
      781 tccaagcctg acctcacggc tgccctgcgt gacgtacgtc agcaatatga aagtgtggct 
      841 gccaagaacc tgcaggaggc agaagaatgg tacaaatcca agtttgctga cctctctgag 
      901 gctgccaacc ggaacaatga cgccctgcgc caggcaaagc aggagtccac tgagtaccgg 
      961 agacaggtgc agtccctcac ctgtgaagtg gatgccctta aaggaaccaa tgagtccctg 
     1021 gaacgccaga tgcgtgaaat ggaagagaac tttgccgttg aagctgctaa ctaccaagac 
     1081 actattggcc gcctgcagga tgagattcag aatatgaagg aggaaatggc tcgtcacctt 
     1141 cgtgaatacc aagacctgct caatgttaag atggcccttg acattgagat tgccacctac 
     1201 aggaagctgc tggaaggcga ggagagcagg atttctctgc ctcttccaaa cttttcctcc 
     1261 ctgaacctga gggaaactaa tctggattca ctccctctgg ttgataccca ctcaaaaagg 
     1321 acattcctga ttaagacggt tgaaactaga gatggacagg ttatcaacga aacttctcag 
     1381 catcacgatg accttgaata a 
 
Spot 5 Analysis from Mass Spectrometry: 
Match to: gi|28595 Score: 73 
aldolase A protein [Homo sapiens] 
Nominal mass (Mr): 11987; Calculated pI value: 8.76, 108 AA. 
Taxonomy: Homo sapiens 
Sequence Coverage: 21%Amino Acid sequence of aldolase A protein [Homo sapiens]: 
Matched peptides shown in Bold Red 
     1 MPYQYPALTP EQKKELSDIA HRIVAPGKGI LAADESTGSI AKRLQSIGTE  
    51 NTEENRRFYR QLLLTADDRV NPCIGGVILF HETLYQKADD GRPFPQVIKS  
   101 KGGVVGIK 
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Coding Sequence of aldolase A protein [Homo sapiens] Accession no. gi|28595: 
        1 atgccctacc aatatccagc actgaccccg gagcagaaga aggagctgtc tgacatcgct 
       61 caccgcatcg tggcacctgg caagggcatc ctggctgcag atgagtccac tgggagcatt 
      121 gccaagcggc tgcagtccat tggcaccgag aacaccgagg agaaccggcg cttctaccgc 
      181 cagctgctgc tgacagctga cgaccgcgtg aacccctgca ttgggggtgt catcctcttc 
      241 catgagacac tctaccagaa ggcggatgat gggcgtccct tcccccaagt tatcaaatcc 
      301 aagggcggtg ttgtgggcat caag 
 
Spot 8 Analysis from Mass Spectrometry: 
Protein View 
Match to: gi|17389815 Score: 672 
Triosephosphate isomerase 1 [Homo sapiens] 
Nominal mass (Mr): 26910; Calculated pI value: 6.45, 249 AA. 
Taxonomy: Homo sapiens 
Sequence Coverage: 62% 
Amino Acid sequence of Triosephosphate isomerase 1 [Homo sapiens]: 
Matched peptides shown in Bold Red 
     1 MAPSRKFFVG GNWKMNGRKQ SLGELIGTLN AAKVPADTEV VCAPPTAYID  
    51 FARQKLDPKI AVAAQNCYKV TNGAFTGEIS PGMIKDCGAT WVVLGHSERR  
   101 HVFGESDELI GQKVAHALAE GLGVIACIGE KLDEREAGIT EKVVFEQTKV  
   151 IADNAKDWSK VVLAYEPVWA IGTGKTATPQ QAQEVHEKLR GWLKSNVSDA  
   201 VAQSTRIIYG GSVTGATCKE LASQPDVDGF LVGGASLKPE FVDIINAKQ 
Coding sequence of Triosephosphate isomerase 1 Accession No. gi|17389815: 
        1 atggcgccct ccaggaagtt cttcgttggg ggaaactgga agatgaacgg gcggaagcag 
       61 agtctggggg agctcatcgg cactctgaac gcggccaagg tgccggccga caccgaggtg 
      121 gtttgtgctc cccctactgc ctatatcgac ttcgcccggc agaagctaga tcccaagatt 
      181 gctgtggctg cgcagaactg ctacaaagtg actaatgggg cttttactgg ggagatcagc 
      241 cctggcatga tcaaagactg cggagccacg tgggtggtcc tggggcactc agagagaagg 
      301 catgtctttg gggagtcaga tgagctgatt gggcagaaag tggcccatgc tctggcagag 
      361 ggactcggag taatcgcctg cattggggag aagctagatg aaagggaagc tggcatcact 
      421 gagaaggttg ttttcgagca gacaaaggtc atcgcagata acgcgaagga ctggagcaag 
      481 gtcgtcctgg cctatgagcc tgtgtgggcc attggtactg gcaagactgc aacaccccaa 
      541 caggcccagg aagtacacga gaagctccga ggatggctga agtccaacgt ctctgatgcg 
      601 gtggctcaga gcacccgtat catttatgga ggctctgtga ctggggcaac ctgcaaggag 
      661 ctggccagcc agcctgatgt ggatggcttc cttgtgggtg gtgcttccct caagcccgaa 
      721 ttcgtggaca tcatcaatgc caaacaatga 
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Spot 9 Analysis from Mass Spectrometry: 
Match to: gi|179780 Score: 314 
Carbonic anhydrase II [Homo sapiens] 
Nominal mass (Mr): 29285; Calculated pI value: 6.87, 260 AA. 
Taxonomy: Homo sapiens 
Accession in NCBI: 
gi|179780 from Homo sapiens 
gi|49456705 from Homo sapiens 
gi|49168536 from Homo sapiens 
Sequence Coverage: 33% 
Amino Acid sequence of carbonic anhydrase II [Homo sapiens]: 
Matched peptides shown in Bold Red 
  1 MSHHWGYGKH NGPEHWHKDF PIAKGERQSP VDIDTHTAKY DPSLKPLSVS 
 51 YDQATSLRIL NNGHAFNVEF DDSQDKAVLK GGPLDGTYRL IQFHFHWGSL 
101 DGQGSEHTVD KKKYAAELHL VHWNTKYGDF GKAVQQPDGL AVLGIFLKVG 
151 SAKPGLQKVV DVLDSIKTKG KSADFTNFDP RGLLPESLDY WTYPGSLTTP 
201 PLLECVTWIV LKEPISVSSE QVLKFRKLNF NGEGEPEELM VDNWRPAQPL 
251 KNRQIKASFK 
Coding Sequence of carbonic anhydrase II [Homo sapiens] Accession No. gi|179780:  
        1 atgtcccatc actgggggta cggcaaacac aacggacctg agcactggca taaggacttc 
       61 cccattgcca agggagagcg ccagtcccct gttgacatcg acactcatac agccaagtat 
      121 gacccttccc tgaagcccct gtctgtttcc tatgatcaag caacttccct gaggatcctc 
      181 aacaatggtc atgctttcaa cgtggagttt gatgactctc aggacaaagc agtgctcaag 
      241 ggaggacccc tggatggcac ttacagattg attcagtttc actttcactg gggttcactt 
      301 gatggacaag gttcagagca tactgtggat aaaaagaaat atgctgcaga acttcacttg 
      361 gttcactgga acaccaaata tggggatttt gggaaagctg tgcagcaacc tgatggactg 
      421 gccgttctag gtattttttt gaaggttggc agcgctaaac cgggccttca gaaagttgtt 
      481 gatgtgctgg attccattaa aacaaagggc aagagtgctg acttcactaa cttcgatcct 
      541 cgtggcctcc ttcctgaatc cttggattac tggacctacc caggctcact gaccacccct 
      601 cctcttctgg aatgtgtgac ctggattgtg ctcaaggaac ccatcagcgt cagcagcgag 
      661 caggtgttga aattccgtaa acttaacttc aatggggagg gtgaacccga agaactgatg 
      721 gtggacaact ggcgcccagc tcagccactg aagaacaggc aaatcaaagc ttccttcaaa 
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Spot 10 Analysis from Mass Spectrometry: 
Protein View 
Match to: gi|54855 Score: 65 
triosephosphate isomerase [Mus musculus] 
Nominal mass (Mr): 27021; Calculated pI value: 6.90, 249 AA. 
Taxonomy: Mus musculus 
Sequence Coverage: 9% 
Amino Acid Sequence of triosephosphate isomerase [Mus musculus]: 
Matched peptides shown in Bold Red 
     1 MAPTRKFFVG GNWKMNGRKK CLGELICTLN AANVPAGTEV VCAPPTAYID  
    51 FARQKLDPKI AVAAQNCYKV TNGPFTGEIS PGMIKDLGAT WVVLGHSERR  
   101 HVFGESDELI GQKVSHALAE GLGVIACIGE KLDEREAGIT EKVVFEQTKV  
   151 IADNVKDWSK VVLAYEPVWA IGTGKTATPQ QAQEVHEKLR GWLKSNVNDG  
   201 VAQSTRIIYG GSVTGATCKE LATPADVDGF LVGGASLKPE FVDIINAKQ 
 
Coding Sequence of triosephosphate isomerase [Mus musculus] Accession no. gi|54855:  
        1 atggcgccta ccaggaagtt cttcgttggg ggcaactgga agatgaacgg gaggaagaag 
       61 tgcctgggag aactcatctg caccctgaac gcagccaacg tgccggcagg caccgaggtg 
      121 gtttgtgcac cgcccaccgc ttacatcgac tttgccagac agaagctgga tcccaaaatt 
      181 gctgtggccg cacagaactg ctacaaagtg accaatgggc ctttcactgg ggaaatcagc 
      241 cctggcatga tcaaagactt aggagccacc tgggtcgtgc tggggcactc agaaagaaga 
      301 catgtctttg gagaatcaga tgagctgatt ggccagaaag tgagccacgc cctagcagag 
      361 ggactcgggg tgatcgcctg catcggggag aagctagacg aaagggaagc cggcatcacc 
      421 gagaaggtcg tgttcgagca aaccaaggtc atcgcagata atgtgaaaga ctggagcaag 
      481 gtggtcctgg cctatgaacc tgtgtgggcc attgggactg gcaagacggc aacccctcag 
      541 caggcacagg aagtacacga gaagctccgg ggatggctga aatccaatgt caatgatggg 
      601 gtggctcaga gcacccggat catttatgga ggttctgtga ctggagcaac ctgcaaagag 
      661 ctggcaacgc cagctgacgt ggacggcttc cttgtgggtg gcgcatctct caagcctgaa 
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Spot 11 Analysis from Mass spectrometry: 
Protein View 
Match to: gi|13325287 Score: 656 
Enolase 1 [Homo sapiens] 
Nominal mass (Mr): 47481; Calculated pI value: 7.01, 434 AA. 
Taxonomy: Homo sapiens 
Accession in NCBI: 
gi|18490320 from Homo sapiens 
gi|13325287 from Homo sapiens 
gi|15990505 from Homo sapiens 
Sequence Coverage: 38% 
Amino Acids: 434 AA. 
 
Amino Acid sequence of Enolase 1 [Homo sapiens]:  
Matched peptides shown in Bold Red 
            1 MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR  
    51 DNDKTRYMGK GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT  
   101 ENKSKFGANA ILGVSLAVCK AGAVEKGVPL YRHIADLAGN SEVILPVPAF  
   151 NVINGGSHAG NKLAMQEFMI LPVGAANFRE AMRIGAEVYH NLKNVIKEKY  
   201 GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV VIGMDVAASE  
   251 FFRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD  
   301 WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV  
   351 TESLQACKLA QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR  
   401 SERLAKYNQL LRIEEELGSK AKFAGRNFRN PLAK 
 
Coding sequence of Enolase 1 [Homo sapiens] Accession No. gi|13325287:  
        1 atgtctattc tcaagatcca tgccagggag atctttgact ctcgcgggaa tcccactgtt 
       61 gaggttgatc tcttcacctc aaaaggtctc ttcagagctg ctgtgcccag tggtgcttca 
      121 actggtatct atgaggccct agagctccgg gacaatgata agactcgcta tatggggaag 
      181 ggtgtctcaa aggctgttga gcacatcaat aaaactattg cgcctgccct ggttagcaag 
      241 aaactgaacg tcacagaaca agagaagatt gacaaactga tgatcgagat ggatggaaca 
      301 gaaaataaat ctaagtttgg tgcgaacgcc attctggggg tgtcccttgc cgtctgcaaa 
      361 gctggtgccg ttgagaaggg ggtccccctg taccgccaca tcgctgactt ggctggcaac 
      421 tctgaagtca tcctgccagt cccggcgttc aatgtcatca atggcggttc tcatgctggc 
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      481 aacaagctgg ccatgcagga gttcatgatc ctcccagtcg gtgcagcaaa cttcagggaa 
      541 gccatgcgca ttggagcaga ggtttaccac aacctgaaga atgtcatcaa ggagaaatat 
      601 gggaaagatg ccaccaatgt gggggatgaa ggcgggtttg ctcccaacat cctggagaat 
      661 aaagaaggcc tggagctgct gaagactgct attgggaaag ctggctacac tgataaggtg 
      721 gtcatcggca tggacgtagc ggcctccgag ttcttcaggt ctgggaagta tgacctggac 
      781 ttcaagtctc ccgatgaccc cagcaggtac atctcgcctg accagctggc tgacctgtac 
      841 aagtccttca tcaaggacta cccagtggtg tctatcgaag atccctttga ccaggatgac 
      901 tggggagctt ggcagaagtt cacagccagt gcaggaatcc aggtagtggg ggatgatctc 
      961 acagtgacca acccaaagag gatcgccaag gccgtgaacg agaagtcctg caactgcctc 
     1021 ctgctcaaag tcaaccagat tggctccgtg accgagtctc ttcaggcgtg caagctggcc 
     1081 caggccaatg gttggggcgt catggtgtct catcgttcgg gggagactga agataccttc 
     1141 atcgctgacc tggttgtggg gctgtgcact gggcagatca agactggtgc cccttgccga 
     1201 tctgagcgct tggccaagta caaccagctc ctcagaattg aagaggagct gggcagcaag 
     1261 gctaagtttg ccggcaggaa cttcagaaac cccttggcca agtaa 
 
 
Spot 12 Analysis from Mass spectrometry: 
Protein View 
Match to: gi|693933 Score: 427 
2-phosphopyruvate-hydratase alpha-enolase; carbonate dehydratase [Homo 
sapiens] 
Nominal mass (Mr): 47421; Calculated pI value: 7.01. Amino Acids: 434 AA 
Taxonomy: Homo sapiens 
Sequence Coverage: 20% 
.Amino Acid sequence of 2-phosphopyruvate-hydratase alpha-enolase; carbonate 
dehydratase [Homo sapiens]: 
Matched peptides shown in Bold Red 
     1 MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR  
    51 DNDKTRYMGK GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT  
   101 ENKSKFGANA ILGVSLAVCK AGAVEKGVPL YRHIADLAGN SEVILPVPAF  
   151 NVINGGSHAG NKLAMQEFMI LPVGAANFRE AMRIGAEVYH NLKNVIKEKY  
   201 GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV VIGMDVAASE  
   251 FSRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD  
   301 WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV  
   351 TESLQACKLA QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR  
   401 SERLAKYNQL LRIEEELGSK AKFAGRNFRN PLAK 
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Coding sequence of 2-phosphopyruvate-hydratase alpha-enolase; carbonate dehydratase 
[Homo sapiens] Accession No. gi|693933: 
        1 atgtctattc tcaagatcca tgccagggag atctttgact ctcgcgggaa tcccactgtt 
       61 gaggttgatc tcttcacctc aaaaggtctc ttcagagctg ctgtgcccag tggtgcttca 
      121 actggtatct atgaggccct agagctccgg gacaatgata agactcgcta tatggggaag 
      181 ggtgtctcaa aggctgttga gcacatcaat aaaactattg cgcctgccct ggttagcaag 
      241 aaactgaacg tcacagaaca agagaagatt gacaaactga tgatcgagat ggatggaaca 
      301 gaaaataaat ctaagtttgg tgcgaacgcc attctggggg tgtcccttgc cgtctgcaaa 
      361 gctggtgccg ttgagaaggg ggtccccctg taccgccaca tcgctgactt ggctggcaac 
      421 tctgaagtca tcctgccagt cccggcgttc aatgtcatca atggcggttc tcatgctggc 
      481 aacaagctgg ccatgcagga gttcatgatc ctcccagtcg gtgcagcaaa cttcagggaa 
      541 gccatgcgca ttggagcaga ggtttaccac aacctgaaga atgtcatcaa ggagaaatat 
      601 gggaaagatg ccaccaatgt gggggatgaa ggcgggtttg ctcccaacat cctggagaat 
      661 aaagaaggcc tggagctgct gaagactgct attgggaaag ctggctacac tgataaggtg 
      721 gtcatcggca tggacgtagc ggcctccgag ttctccaggt ctgggaagta tgacctggac 
      781 ttcaagtctc ccgatgaccc cagcaggtac atctcgcctg accagctggc tgacctgtac 
      841 aagtccttca tcaaggacta cccagtggtg tctatcgaag atccctttga ccaggatgac 
      901 tggggagctt ggcagaagtt cacagccagt gcaggaatcc aggtagtggg ggatgatctc 
      961 acagtgacca acccaaagag gatcgccaag gccgtgaacg agaagtcctg caactgcctc 
     1021 ctgctcaaag tcaaccagat tggctccgtg accgagtctc ttcaggcgtg caagctggcc 
     1081 caggccaatg gttggggcgt catggtgtct catcgttcgg gggagactga agataccttc 
     1141 atcgctgacc tggttgtggg gctgtgcact gggcagatca agactggtgc cccttgccga 
     1201 tctgagcgct tggccaagta caaccagctc ctcagaattg aagaggagct gggcagcaag 
     1261 gctaagtttg ccggcaggaa cttcagaaac cccttggcca agtaa 
 
